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Since the total synthesis of FR901464 was achieved in our group, its structure-activity 
relationships were extensively studied through analogue syntheses. Here I described the 
syntheses and biological activities of two acetal and two cyclopropane analogues. Although the 
acetal analogues were less potent than their parental analogue meayamycin, they retained 
nanomolar activity against MCF-7 cells. Meanwhile, the methyl groups on the acetal ring 
slightly influenced the activities. Compared to analogue meayamycin C, these two cyclopropane 
analogues were equipotent towards MCF-7 cell lines, which implied that the cyclopropane 
moiety might not inhibit the binding to the targets. 
I also developed an efficient strategy to synthesize the C1'-C5' side chain with Ando’s 
reagent. Subsequently, a convergent strategy was used to prepare a new acetal analogue over 20 
steps with 12 steps in the longest linear sequence. 
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SYNTHESIS AND BIOLOGICAL STUDIES OF FR901464 ANALOGUES 
1.1 INTRODUCTION OF FR901464 
1.1.1 Isolation and characterization of FR901464 
The targets of current commercially available cancer drugs include DNA, nuclear hormone 
receptors, kinases, the proteasome, and microtubules.
1
 Because the low specificity of these 
chemotherapeutic agents between cancer and normal cells leads to high toxicity, exploring new 
cancer therapy targets is of paramount importance.
2-6
 The transcriptional pathway has emerged 
as a promising cancer target.
7-9
 In order to search for new agents that regulate the transcriptional 
pathway of cancer cells, the Nakajima group at the Fujisawa Pharmaceutical Company employed 
a new screening system to select transcriptional regulators. In the screening system, a plasmid 
with the promoter of simian virus 40 (SV40) upstream of a chloramphenicol acetyltransferase 
(CAT) reporter gene was stably transfected into human breast adenocarcinoma MCF-7 cells.
10
 
Using this screening system, FR901463, FR901464 and FR901465 (Figure 1) were identified in 
the bacterium Pseudomonas sp. No. 2663. After isolation, the effects of these compounds were 
examined on different cancer cells.
10
 The results showed that FR901464 was the most promising 
antiproliferative agent among these three compounds, with IC50 values of 0.31−1.69 ng/mL 
against HCT-116 (human colon carcinoma cells), SW480 (human colon adenocarcinoma cells), 
A549 (human lung carcinoma cells), MCF-7 (human breast adenocarcinoma cells), and P388 
 2 
(murine leukemia cells) cancer cell lines. FR901464 also inhibited the growth of tumors from 
P388, A549, Colon 38 (murine colon adenocarcinoma cells) and Meth A (murine fibrosarcoma 
cells) cells in mice in a dose range of 0.056−1 mg/kg.11-12 
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Figure 1. Structures of FR901463, FR901464, and FR901465 
 
In order to study the mode of action of FR901464, its biological activities were examined 
by the Nakajima group. The accumulation of CAT protein in the aforementioned MCF-7 cell line 
was monitored upon treatment of these cells with FR901464. The CAT protein expression 
increase was detected at 6 h after drug treatment and continued for 18 h. In the FR901464-free 
control cells, no CAT protein accumulation was observed. The analysis of the cell cycle 
distribution of MCF-7 cells treated with FR901464 showed G1 and G2/M phase arrest.
13
 In 
contrast, the known DNA synthesis inhibitors adriamycin and camptothecin induced S phase 
arrest, and the microtubule modulator taxol induced G2/M phase arrest.
11
 The differences in cell 
cycle distribution caused by FR901464 and these well-known anticancer agents indicated a 
unique mode of action of FR901464. 
The unique biological activities of FR901464 intrigued the scientists to identify the 
targets. In the Kitahara group, a methylated FR901464 derivative named spliceostatin A (Figure 
2) was synthesized and found to be more active than the parent compound. The better activity 
 3 
was due to the higher chemical stability of the methyl acetal compared to the labile hemiacetal of 
FR901464.
14
 Subsequently, they synthesized the biotinylated derivative of spliceostatin A 
(Figure 2). Although the biotinylated spliceostatin A was less potent than FR901464, the 
Yoshida group successfully used the compound as a probe to isolate the cellular target of 
FR90146. The results showed that the FR901464 and its derivatives inhibited in vitro splicing by 
binding to splicing factor 3b (SF3b),
15
 a subcomplex of the U2 small nuclear ribonucleoprotein 
in the spliceosome.
16
 
SF3b, with a mass of ~450 kD, is composed of seven proteins, SF3b155, SF3b145, 
SF3b130, SF3b49, p14, SF3b14b and SF3b10, and responsible for the recognition of the pre-
messenger RNA’s branch site. At the beginning of the splicing, several SF3b proteins bind to the 
vicinity of the branch point, and the protein p14 is directly cross-linked to the adenosine of the 
intron. SF3b plays a vital role for the accurate excision of introns from pre-messenger RNA to 
form mature RNA.
17
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Figure 2. Structures of spliceostatin A and biotinylated spliceostatin A 
 
Since SF3b was identified as the target of FR901464, other anticancer agents were also 
found to bind to the U2 subunit. In 2004, the Sakai group at Eisai Co., Ltd., using a placental 
alkaline phosphatase (PLAP) reporter gene controlled by a vascular endothelial growth factor 
(VEGF) promoter, screened seven unique 12-membered macrolides, named pladienolides, from 
the culture broth of Streptomyces platensis Mer-11107.
18-19
 Of the seven compounds, 
 4 
pladienolide B (Figure 3) was the most potent antiproliferative agent with GI50 values of 0.4−9.8 
nM against 39 human cancer cell lines. Six drug-resistant cell lines, P388/CPT, P388/ETP, 
P388/CDDP, P388/VCR, HCT-116/5-FU and MES-SA/Dx5, were examined. Pladienolide B 
showed similar anticancer activity against these drug-resistant cell lines and the parental cell 
lines.
20
 In 2007, the Mizui group in Eisai Co., Ltd. used biotin-tagged pladienolide B (Figure 3) 
as a probe to treat HeLa cells and revealed that spliceosome associated protein 130 in the SF3b 
complex was a target of pladienolide B.
 21
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Figure 3. Structures of pladienolide B and biotin-tagged pladienolide B. 
 
In summary, FR901464 and pladienolide B, screened with different methods, proved to 
target spliceosome subcomplex SF3b and inhibit pre-mRNA splicing and showed high 
antiproliferative potency in several cancer cell lines. The spliceosome may be a new target for 
cancer. 
1.1.2 Total synthesis of FR901464  
The total synthesis of FR901464 was first achieved by the Jacobsen group in 2000 (Scheme 1). 
The acid fragment 2 was prepared from commercially available 4-(trimethylsilyl)-3-butyn-2-one 
1 with the stereocenter constructed by a Noyori asymmetric hydrogenation.
22
 Fragment 5 was 
synthesized from diene 3 and aldehyde 4 via an asymmetric chromium-catalyzed hetero-Diels-
 5 
Alder reaction.
23
 The synthesis of fragment 8 began from propanone 6 and dienyne 7 through 
cycloaddition,
23
 Rubottom oxidation,
24
 hydrozirconation and epoxidation. With fragment 5 and 8 
in hand, a Negishi coupling
25
 reaction was applied. After the installation of side chain 2, the 
synthesis of FR901464 was achieved in a total of 37 steps, with 19 steps in the longest linear 
sequence.
26-27
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Scheme 1. Jacobsen’s total synthesis of FR901464 
 
The Kitahara group employed a chiral pool strategy to complete the second total 
synthesis of FR901464.
28
 Because several problems were encountered in the synthesis, such as a 
low yield in the Julia olefination
29
 and poor regioselectivity during the epoxidation, they revised 
the key steps in their second generation of total synthesis.
30
 In Kitahara’s second total synthesis 
of FR901464 (Scheme 2), the acid fragment 10 was prepared from (S)-lactate 9 in four steps. 
Garner’s aldehyde 11,31 with set C14 and C15 two stereocenters of FR901464, was used to 
 6 
synthesize sulfone 12, in which the stereocenters C11 and C12 were established with platinum-
catalyzed hydrogenation. The synthesis of fragment 14 began with 2-deoxy-D-glucose 13 
containing C4 and C5 stereocenters and was finished in 15 steps. After fragments 10 and 12 were 
coupled by amidation, the resulting product was subjected to modified Julia olefination followed 
by four additional steps to produce FR901464. The total synthesis was completed in 41 total 
steps, with 22 steps in the longest linear sequence.
30
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Scheme 2. Kitahara’s total synthesis of FR90464 
 
The Koide group developed a more concise way to accomplish the total synthesis of 
FR901464 (Scheme 3). The acid side chain 2 was synthesized from propargyl alcohol 15 with 
the C4' stereocenter established through CBS reduction.
32
 The synthesis of the tetrahydropyran 
ring 17 began with the L-threonine derivative 16 and was completed in 9 steps. Intermediate 19 
was prepared from propargyl alcohol 15 and methallyl bromide 18 in 11 steps. With the three 
fragments in hand, an amidation reaction assembled acid 2 and protected amine 17 to form an 
advanced intermediate, which was subjected to two more steps followed by cross olefin 
 7 
metathesis to give FR901464. The total synthesis of FR901464 was achieved in 29 steps, with 13 
steps in the longest linear sequence.
1,33
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Scheme 3. Koide’s total synthesis of FR901464 
1.1.3 Previous synthesis and biological activity of FR901464 analogues 
The structure-reactivity relationship (SAR) of FR901464 has been partially elucidated through 
analogue synthesis (Figure 4). The Jacobsen group synthesized analogues 20 24 to study the 
side chain, the hemiacetal, and the epoxide, respectively. FR901464 and these analogues were 
tested for their anticancer effects against Tag Jurkat cells.
27
 The GI50 value of compound 20 was 
1700 nM, which was three orders of magnitude more than that of FR901464  (GI50 = 2.0 nM), 
meaning that the side chain plays a key role for the biological activity of FR901464.
27
 
Compound 21, the C4' epimer of FR901464, was less potent than the parent compound by 15-
fold.
27
 The activity of 22 was the same as the natural product, demonstrating that equilibration to 
an open chain ketone was not essential for biological activity. The activity of compound 23 
 8 
bearing an inverted stereocenter at C3 dropped two orders of magnitude. Furthermore, after the 
epoxide was replaced by a cyclopropyl moiety, the resulting compound 24 completely lost 
biological activity, which suggested that epoxide moiety was vital to the biological activity of the 
compound.
27
 
The Takahashi group synthesized two FR901464 derivatives, cyclopropane 25 and ω-
amine ester 26, by modifying the C4-hydroxy group and C4'-ester group of FR901464 with 
amino-alkyl group. The EL-4 mouse lymphoma T-cell line was used to test the biological 
activities of the two compounds and FR901464. The GI50 values of 25 and 26 were 500 nM and 
83 nM, respectively, which were two orders and one order of magnitude higher than that of 
FR901464, respectively.
34
 
The Kitahara group used a cytomegalovirus (CMV) promoter-driven transcription system 
to test two FR901464 analogues, spliceostatin A (Figure 2) and alkene 27. Spliceostatin A was 
more potent than FR901464, but derivative 27 almost completely lost biological activity, which 
further supported the significant contribution of the epoxide moiety to the biological activity of 
FR901464.
14
 
The lability of FR901464 prompted the Koide group to examine the stability of fragment 
19. The half-life of 19 is only 8 h and 4 h in pH 7.0 and 7.4 buffer, respectively.
1
 The following 
mechanistic study implied that the hemiacetal functionality was unstable. The Koide group 
replaced the C1-hydroxy group with a methyl group and found the resulting analogue 28 
(meayamycin) (GI50, 10.2 pM) was 100-fold more active than FR901464 (GI50, 1.1 nM) in MCF-
7 cells.
1
 After this discovery, the Koide group synthesized a series of analogues 29, 30 and 31. In 
alcohols 29, 30 and methyl ether 31, the epoxide moiety was substituted with oxygen-containing 
groups. These analogues showed no anticancer activity against MCF-7 cells even at 10 μM. This 
 9 
result was consistent with that from the Jacobsen and Kitahara groups and suggested that the 
epoxide moiety played a vital role in the antiproliferative activity. 
For the purpose of simplifying the left-hand ring and studying its SAR, the Koide group 
prepared gem-dimethyl analogues 32 and 33, which exhibited GI50 values of 0.30 and 2.5 nM, 
respectively. Compared with meayamycin 28, the decreased biological activities were attributed 
to the loss of hydrophobicity caused by removing the methyl group and replacing the methylene 
group with oxygen. 
35
  
Alcohols 34 and 35 were prepared to examine the importance of the C4' stereocenter and 
the acetyl group to the biological activity. The activity of 34 was 24 times (GI50 = 0.48 nM) 
lower than that of meayamycin, while the GI50 of analogue 35 dropped one order of magnitude in 
comparison with meayamycin. The results demonstrated that the acetyl group and the C4' 
stereocenter played a crucial role in the mode of action of FR901464. After deacetylation, the 
improved hydrophilicity might contribute to the loss of potency. In addition, the C4' free alcohol 
in these two compounds can form intramolecular hydrogen bonds with C1' carbonyl, which 
facilitates the change of the orientation 5'-methyl group and C4'-hydrogen. The change of 
conformation diminished the biological activity of the analogues. The degradation of 
meayamycin in human serum showed that the acetyl group could be hydrolyzed, with a half life 
of 2 h.
36
 Compound 36 (meayamycin B) was then synthesized by replacing the acetyl group with 
morpholine-based carbamate to improve the stability.
37-39
 The increased stability would extend 
the half-life. In turn, the actual concentration of the compound in vivo or in vitro was 
hypothesized to increase, and the potency of the compound would therefore be enhanced. As 
anticipated, the biological activity of compound 36 was improved in comparison to compound 28 
against several cell lines.
35
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Figure 4. FR901464 analogues 
 
Chemical biology studies uncovered that FR901464 and pladienolide B have a very 
similar mode of action.
15,21
 Inspired by these findings, the Webb group used their model to 
 11 
design a new compound 37.
40
 In the compound, the highly substituted left tetrhydropyran ring 
was replaced with a cis-1,4-substituted cyclohexyl group, eliminating the C4-hydroxy group.
40
 
Although compound 37, with an IC50 of 2.29 μM against MCF-7 cell lines, was less potent than 
FR901464, it was very synthetically tractable. Compound 37 also showed a biological profile 
similar to that of FR901464, which suggested that it might have the same mode of action as 
FR901464.
40
 Based on their discovery, the Webb group synthesized a series of compounds to 
further understand the SAR. Four carbamate derivatives containing a basic amine group were 
prepared (Figure 5), which were hypothesized to have enhanced solubility and esterase 
resistance.
41
 The carbamate derivatives 38a-b showed, however, less potency against JVM-2 cell 
lines in comparison to 37.
41
 They also synthesized a set of ester analogues 39a-i, and studied the 
biological activity of 39a in which the acetyl was replaced with a more hindered isobutyryl 
moiety to improve stability in vivo.
41
 In addition, compound 39a should preserve high chemical 
stability in phosphate buffered saline (pH 7.4, t1/2 = 1200 h at 22 °C). Compound 39a exhibited 
selective antitumor activity against certain adult and pediatric cancer types.
41
 Due to limited 
solubility of compound 39a in water or aqueous buffer,
41
 a cyclic acetal analogue 40 was 
designed to improve the solubility. Compound 40 was more soluble than 39a in phosphate 
buffered saline, and had biological activity similar to 39a against JeKo-1 cell lines. Both 39a and 
40 displayed mRNA splicing inhibition activity, and presumably had similar molecular targets of 
FR901464 or pladienolide B.
41
  
 12 
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Figure 5. Structures of 37 and its analogues 
 
In summary, the replacement of the C1-hydroxy group (Figure 6) with a methyl group 
improved the potency of analogues, which indicates that the open-chain ketone isomer is not 
responsible for the cytotoxicity of FR901464. The C3-expoide group is important for the 
biological activity of FR901464. Protection of the C4-hydroxy group with a methyl group 
diminished the biological activity. Cyclopropanation of the C8-C9 double bond induced loss of 
the anticancer potency. Modifying the left-hand pyran ring caused a decrease in the biological 
activity because of diminished hydrophobicity and alteration of conformations. Last but not least, 
the biologically labile C4'-acetate is important to the FR901464, but it can be substituted with a 
morpholine-based carbamate to enhance stability and potency. 
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Figure 6. Structure-activity relationship of FR901464 
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1.2  SYNTHESIS AND BIOLOGICAL ACTIVITY OF FR901464 ANALOGUES 
1.2.1 The synthesis and biological activity of acetal analogues 
1.2.1.1 Introduction of acetal analogues 
In order to develop a more efficient synthesis, the Koide group has been engaged in the design 
and synthesis of simplified but potent analogues of FR901464. During this work, acetal analogue 
33 (Figure 4) was synthesized in 21 steps by Dr. Miaosheng Li.
35
 In analogue 33, the left-hand 
pyran ring was replaced by an acetal ring that could be easily obtained. Although the 
replacement resulted in the loss of biological activity, in comparison with its parent analogue 28 
(meayamycin), analogue 33 still has a nanomolar IC50 value (2.5 nM).
35
  
The current study examines the influence of the acetal ring on the biological activity. I 
decided to synthesize acetal analogues 41 and 42 to probe the impact of substituents at positions 
13 and 15 (Figure 7). 
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15
 
Figure 7. Structures of acetal analogues 41 and 42 
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1.2.1.2 Synthesis of acetal analogues 
Initially, efforts toward the synthesis of analogue 41 begun by converting compound 45 from 
43
33
 (Scheme 4). Oxazolidine 43 was treated with DIBALH to give Garner’s aldehyde 44,31,42-43 
which was subjected to nucleophilic addition with MeLi. The addition reaction gave the 
undesired diastereoisomer 45 as a major compound, however, via a non-chelation controlled 
Felkin-Anh model
44-46
 (Figure 8), in which the methyl nucleophile attacked on the less hindered 
re-face to give the trans product.
47
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Scheme 4. Nucleophilic addition to Garner’s aldehyde 
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Figure 8. Model of methyl nucleophile addition to Garner’s aldehyde 
 
Due to the unsuccessful nucleophilic addition to Garner’s aldehyde, I started to search for 
a new route. I discovered that olefin 46
33
 could be treated with NIS to afford desired iodide 47a 
(Scheme 5) as the major compound via iodocyclization
48-50
, and a minor compound was 
tentatively assigned as iodide 47b (4.6-6:1 dr). 
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Scheme 5. Regio- and diastereoselective iodocyclization of 46 
 
To explain the diastereoselectivity of the iodocyclization, two possible transition states 
were proposed (Figure 9). If iodine attacked the -face of the olefin in 46, intermediate 
iodiranium 48a would be formed. The carbonyl oxygen of the carbamate attacked the C13-I 
bond backside to give compound 47a. Intermediate iodiranium 48b, formed by iodine attacking 
on the -face of the olefin, had a higher activation energy because of the steric interaction 
between Ha and Hb in the transition state.  
N
Boc
O
I N
Boc
O
I
48a 48b  
                                                            
Figure 9. Iodonium transition states 48a and 48b 
 
The subsequent reduction of the iodide compound 47 proved to be problematic (Table 1). 
The palladium-catalyzed dehalogenation reaction
51
 was applied to reduce 47, but no reaction 
happened at room temperature or elevated temperature. When Et3SiH was used as a solvent at 80 
°C, the thin layer chromatography showed an intractable result. Then, two conditions, LiAlH4
52
 
and AIBN/Bu3SnH,
53
 were employed to remove the iodine; however, both of these conditions 
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gave intractable products. I therefore applied a Pd/C catalyzed-hydrogenation
54
 condition to 
reduce the iodide. In order to neutralize the side product acid HI, bases NaOH and NaHCO3 were 
first applied, but led to a low yield of oxazolidin 49. Et3N was then used, and the reaction 
proceeded smoothly to provide 49 in 86% yield. 
 
Table 1. Reduction of iodide 47a 
N
O
OO
N
O
OO
I
conditions
47a 49  
entry catalyst (equiv) reagent (equiv) solvent temperature time  result 
1 PdCl2 (5 mol%) Et3SiH (1.5) Et2O rt 2 h no reaction 
2 PdCl2 (5 mol%) Et3SiH (1.5) toluene reflux 2 h no reaction 
3 PdCl2 (5 mol%) Et3SiH (1.5) none 80 °C 2 h 
intractable 
products 
4 none LAH (2.0) THF rt 1 h 
intractable 
products 
5 none 
AIBN(0.2) 
Bu3SnH (3.0) 
toluene rt 12 h 
intractable 
products 
6 Pd/C (5 mol%) 
NaOH (1.2), 
H2 (1 atm) 
EtOH rt 6 h 15% 
7 Pd/C (5 mol%) 
NaHCO3 (2.0), 
H2 (1 atm) 
EtOH rt 1.2 h 46% 
8 Pd/C (5 mol%) 
Et3N (6.0), 
H2 (1 atm) 
EtOH rt 22 h 86% 
 
Acidic hydrolysis of 49 gave alcohol 50 (Scheme 6),
44
 which was further exposed to 
KOH to generate diol 51. Due to the high water solubility of 50 and 51, it was laborious to 
extract these two intermediates from the aqueous layer. Once the Boc-protected compound 52 
was formed, purification became easier and more efficient. Subsequently, 52 was treated with 3-
butenal diethyl acetal and a catalytic amount of CSA to furnish segment 53. 
 18 
With 53 in hand, amine 54 was afforded after removal of Boc (Scheme 6), and 
subsequently subjected to a coupling reaction with fragment 2. The resulting intermediate olefin 
55 was exposed to methacrolein and ruthenium complex 56
55-56
 to furnish aldehyde 57 via a 
cross metathesis reaction. The Wittig reaction was then used to convert aldehyde 57 to diene 58. 
The acetal analogue 41 was then completed by exposure of diene 58 to the right fragment 59 and 
pre-catalyst 56 in 22% yield. 
 
HCl, H2O,
THF
OH OH
NH2
OH OH
NHBoc
50 51 52
HN
OO
HO
O
O
TFA.H2NO
O
N
H
O
AcO
TFA, 
CH2Cl2,
quant.
55
O
O
N
H
O
AcO O
methacrolein,
56, 84%
57
O
O
N
H
O
AcO
Ph3PCH3Br, KO
tBu,
THF, 0 C, 67%
58
O
O
N
H
O
AcO O
O
HO
O
O
HO
59
56, benzoquinone,
DCE, 40 C, 22%
Ru
NN
Cl
(
O NO2
Me
Me
Me
Me
Me
Me
Cl
56
5354
41
HATU, DIPEA,
MeCN, 69%
KOH, H2O,
 
dioxane CSA, CH2Cl2,
0 C, 66%
Boc2O,
42%, 2 steps
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OEt
EtO
N
O
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49
O
O
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Scheme 6. Synthesis of 41 
 
At this stage, two acetal analogues, 33 and 41, were available containing one and two 
methyl groups on the cyclic acetal, respectively. The third acetal analogue 42 without a methyl 
group on the cyclic acetal (Figure 7) was also synthesized. Synthesis of analogue 42 began with 
the preparation of fragment 61 (Scheme 8). With commercially available amine 60, 3-butenal 
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diethyl acetal and 0.1 equivalent of p-TsOH were used in attempts to form the acetal ring,
57
 but 
no desired product was obtained. I envisioned that the free amine might influence the reaction by 
forming five member ring,
58
 and could be protected in situ with excess acid. After the amount of 
p-TsOH was increased to 1.3 equivalents, 61 was produced with 13% yield. Because of the low 
yield of acetal formation with the free amine, 60 was protected by using Boc2O. The resulting 
diol 62 was subjected to acetal formation with 3-butenal diethyl acetal to afford acetal 63 (cis : 
trans = 61 : 39). After recrystallization, the diastereoisomeric ratio increased from 61:39 to 
83:17. The Boc group was then removed with TFA to afford 61 in 49% yield over three steps. 
 
HO OH
NH2 O
O
TFA.H2N
HO OH
NHBoc
60 61
62
(Boc)2O, NaHCO3,
THF/H2O, 86 %
3-butenal diethyl acetal,
CSA, CH2Cl2, 0 C, 
dr = 61:39, 72%
O
O
BocHN
63
TFA, CH2Cl2,
quant.
3-butenal diethyl acetal,
p-TsOH, CH2Cl2/THF
 
Scheme 7. Synthesis of 61 
 
The NMR spectra for cis and trans-63 showed the existence of an intramolecular 
hydrogen bond (Figure 10) in cis-63, which accounts for the preference of the cis isomer.
59
 The 
chemical shift of N-H in cis-63 is 5.51 ppm (broad doublet); by contrast, trans-63 presents a free 
N-H group with a broad peak at 4.15 ppm. 
O
O
BocN
trans-63
O
O
BocHN
cis-63
O
O
BocHN
trans-63
O
OBocHN
cis-63
H
 
Figure 10. H-bonding potential for acetal 63 
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Acetal analogue 42 was then completed as follows. Intermediate 61 was synthesized from 
58 and acid 2 (Scheme 8) and further treated with methacrolein and 53 to afford aldehyde 62. 
The diene fragment 63, constructed via the Wittig reaction from 62, was subjected to metathesis 
reaction with 56 and 53 to afford the acetal analogue 38.  
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Scheme 8. Synthesis of 42 
1.2.1.3  The biological activity of acetal analogues 
The anticancer activities of these two acetal analogues 41 and 42 against MCF-7 cells (Table 2) 
were examined by Sami Osman in the Koide group. The GI50 values for 41 and 42 were 
determined to be 85 and 19 nM, respectively. To account for their different biological activities, 
the conformation differences of the two compounds were studied. Previously, the Vasella group 
examined the conformations of compound 70 in water and found that the 70N-ax had an 
unexpectedly high ratio of 33% (Scheme 9). The hydrogen bonding between the amide hydrogen 
and the oxygen presumably stabilized the conformer 70N-ax.
60
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Table 2. Antiproliferative activities of 28, 32, 33, 41 and 42 against MCF-7 cells 
FR901464 analogues GI50 (nM) 
28
O
N
H
O
AcO O
HO
O  
0.020 
O
N
H
O
AcO O
HO
O
32
 
0.30 
O
O
N
H
O
AcO O
HO
O
33
 
2.5 
O
O
N
H
O
AcO O
O
HO
41
 
85 
O
O
N
H
O
AcO O
O
HO
42
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(2)
 
Scheme 9. Conformations of compound 70 and FR901464 
 
The conformer FR901464N-ax would be even more favored because the severe 1,3-
interaction between substituents on C11 and C15 in FR901464N-eq. FR901464N-ax was supposed 
to be the dominating conformer. With this hypothesis, the coupling constants of protons in the A 
rings in left side fragments of 67, 68 and 69 of the corresponding analogues 28, 32 and 33 were 
examined (Figure 11) (CD3OD was used as solvent).
35
 For 67, J11-12 was 2.8 Hz and J14-15 was 
2.1 Hz, indicating a chair-like structure. For 68, J11-12 was 3.5 Hz and J14-15 was 1.6 Hz, and     
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J14-15s  in acetals 69 and 58 were 1.8 and 1.5 Hz, respectively, thus indicating that the bond 
angles are similar in all four structures.
35
  Therefore, the variation in their biological activity is 
not due to the difference of conformation in the A-ring. 
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Figure 11. Structures of 58, 67, 68 and 69 and couplings in the A rings 
 
An additional reason behind the decrease in biological activity may be the diminished 
hydrophobicity of the A ring. The effect of this trend was demonstrated with compounds 28, 32, 
33 and 42 (Figure 12). Hydrophobicity was reduced in comparison to 28 by eliminating C12-
methyl group in 32, replacing C12 with an oxygen atom in 33, removing another methyl group at 
C15 position in analogue 42. With a corresponding loss of hydrophobicity, these four analogues’ 
GI50 values increased from 0.020 to 19 nM against MCF-7 cells. This indicated that the 
hydrophobicity of the compounds played a vital role for the anticancer activities. In addition, the 
roles of substituents at positions 13 and 15 were probed. Replacement of a hydrogen at C13 with 
a methyl group was detrimental to the biological activity. The deletion of the C15 methyl group 
 23 
also caused a loss of the antiproliferative activity. The syntheses of these analogues investigated 
the significance of the substitutents at positions 12, 13 and 15. 
 
O O
O
O
O
O
28 32 33 42
Diminishing hydrophobicity  
Figure 12. The hydrophobicity of the left-hand ring in analogues 28, 32, 33 and 42. 
 
Compared to compound 40 synthesized by the Webb group, analogue 42 retained the C4-
hydroxy group. Compound 40 showed nanomolar activity against JeKo-1 cell lines (GI50 = 150 
nM), while the GI50 of 42 against MCF-7 cells was 19 nM. Unfortunately, because these two 
compounds had been tested in different cell lines, it was difficult to determine the importance of 
the C4-hydroxy group to the biological activity of FR901464. However, compound 40 showed 
activity against JeKo-1 cell lines very similar to that of compound 39a, which was less potent 
than 42 against MCF-7 cells. It can thus be speculated that compound 40 is less active than 
analogue 42 in MCF-7 cell lines, and the C4-hydroxy group possibly benefits the biological 
activity of FR901464. 
In conclusion, acetal analogues 41 and 42 were synthesized and tested in MCF-7 cells. 
The results suggested the methyl groups on the acetal ring moderately influence the biological 
activity of the acetal analogues. 
 
O
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41 (GI50 = 85 nM) 42 (GI50 = 19 nM)  
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1.2.2 The synthesis and biological activity of cyclopropane analogues 
1.2.2.1 Introduction 
Cyclopropyl groups occurring in natural products or in synthesized compounds can sometimes 
improve the biological activity of compounds.
61-62
 Several cyclopropane-containing analogues of 
epothilone 
63-64
 and (+)-discodermolide
65
 have been synthesized and proven to improve or 
maintain the biological activities as compound to the parent molecules. However, the 
cyclopropane moiety also induced the activity loss of compounds, such as cis- and trans-2- 
(aminomethyl) cyclopropane carboxylic acids
66
 and several cyclopropane analogues of 
penciclovir.
67
 
 The diene moiety in FR901464 has two faces, which might have different preferences to 
the target. In addition, the 1,3-diene was found to be subject to facile isomerization under acidic 
conditions,
1
 which might also occur in cells. I questioned whether the trans, trans-diene moiety 
was actually the biological active species. To address these hypothesis, cyclopropane analogues 
71 and 72 (Figure 13) were designed in which either face of the diene was blocked and the 
cyclopropane moiety also maintained the trans arrangement afforded by the C8-C9 double bond. 
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Figure 13. Structures of analogues 71, 72 and 73 
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1.2.2.2 The synthesis of cyclopropane analogues 
Efforts towards these two analogues were focused on building the cyclopropane ring. I started 
from intermediate 17
1 
and 2-methyl-2-propen-1-ol (Scheme 10), which were treated with 
ruthenium complex 56 to give allylic alcohol 74. Unfortunately, the reaction suffered from a 
slow rate and poor selectivity (E:Z = 4:1). Instead of 2-methyl-2-propen-1-ol, methacrolein was 
alternatively chosen for the metathesis reaction,
68
 and enone 75 was made in 53% yield with an 
improved selectivity (E:Z = 10:1). Enone 75 was reduced with DIBALH to provide 74 in 
quantitative yield. A diastereoselective Simmons-Smith reaction
69
 with chiral ligands 76 or 77 
transferred 74 to 78 or 79, respectively, with moderate selectivity. Two possible transition states 
for the diastereoselective cyclopropanation of 74 are presented as structures 80a and 80b in 
Figure 14. In conformation 80b, the double bond is folded away from the amide carbonyl group 
that loosely connects with the zinc, while zinc carbenoid is brought in a closer proximity to the 
amide carbonyl group in conformation 80a. Compared to 80b, 80a has lower energy and is 
therefore predicted to be the excess diastereomer.
69
 The C8 methyl group has strong interaction 
with the zinc reagent in the transition state 80a.
69
  
OH
56, DCE, 20 %
E:Z = 4:1
O
BocHN
OH
methacrolein,
53, 53%,
E:Z = 10:1
O
BocHN
O
17
75
74
DIBALH, CH2Cl2, 
-78 oC, quant.
O
BocHN
OH
ZnEt2, 76, CH2I2, 
CH2Cl2, 0 C to rt, 
75%, dr = 11:1
O
B
O
CONMe2Me2NOC
Bu
78
76
O
B
O
CONMe2Me2NOC
Bu
77
ZnEt2, 77, CH2I2,
CH2Cl2, 0 C to rt, 
88%, dr = 11:1
O
BocHN
OH
79
O
BocHN
 
Scheme 10. Synthesis of 75 and 76 
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Figure 14. Transition-state model for the cyclopropanation  
 
After 78 was deprotected with TFA, the resulting amine 81 was coupled with acid 2 to 
produce 82 (Scheme 11). Subsequent Dess-Martin
70
 oxidation of 82 afforded 83, and the 
aldehyde was then exposed to the Wittig reagent to give 84. Transformation of 84 into carbamate 
85 was accomplished through methanolysis of the acetate, activation of the resulting alcohol with 
CDI, and nucleophilic substitution with morpholine.  
Dess-Martin,
CH2Cl2, 
0 C, 70%
O
N
H
OH
O
AcO
O
N
H
O
O
AcOO
N
H
O
AcO
O
TFA.H2N
OH
1) K2CO3,MeOH, 
0 C,1 h,
2) CDI; morpholine, 
CH2Cl2, 62% two steps
O
N
H
O
ON
O
O
81 82
8384
85
TFA, 
CH2Cl2,
quant.
Ph3PCH3Br,
KOtBu,
THF, 0 C, 80%
2, HATU, 
DIPEA,
MeCN, 48%
O
BocHN
OH
78
 
Scheme 11. Synthesis of 85 
 
I encountered some difficulties in the last step metathesis reaction because of the highly 
substituted allylic position. Fragment 59 (Table 3) was first employed as a cross metathesis 
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partner at 40 °C, but no desired product was observed. Subsequently, the temperature was 
increased to 70 °C, giving the dimer of 59 as the major product. Due to the introduction of the 
cyclopropyl group, the left fragment 85 was sluggish in the metathesis reaction, but 59 was very 
reactive to the ruthenium complex. Reducing the reactivity of the right fragment was a practical 
way to solve the problem. Moreover, it was previously found that when 86 was applied in the 
metathesis reaction, the corresponding product was obtained smoothly without significant 
dimerization of 86.
71
 Inspired by this result, fragment 86 was then used to couple with 85 via a 
metathesis reaction in toluene at 70 °C, and analogue 71 was formed in 22% yield.  
Table 3. Synthesis of cyclopropane analogue 
O
O
HO
right fragment temperature solvent result
O
O
MeO
40 to 70 C DCE
dimerization of 
right fragment
70 C toluene
22% after 
one cycle
59
86
O
N
H
O
ON
O
O
59 or 86,
56, benzoquinone
O
N
H
O
O O
O
MeO
N
O
O
85 71
Ru
NN
Cl
(
O NO2
Me
Me
Me
Me
Me
Me
Cl
56
 
 
I applied a similar strategy to synthesize analogue 72 (Scheme 12). Amine 87, produced 
from 79, was assembled with acid 88 via a coupling reaction to afford alcohol 89. Dess-Martin 
oxidation of compound 89 gave aldehyde 90 with a moderate yield. Compound 90 was subjected 
to the Wittig reaction to provide left fragment 91, which was coupled with 86 under the same 
conditions as before to furnish analogue 72 in 22% yield.  
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Scheme 12. Synthesis of 72 
1.2.2.3 The biological activity of cyclopropane analogues 
In antiproliferative experiments, MCF-7 cells were treated with cyclopropane analogues 71 and 
72. Analogue 73, with a GI50 of 0.38 nM,
71
 was used as a reference compound. The results 
showed that analogues 71 and 72 exhibited very similar GI50 values, 15 and 10 nM, respectively. 
Although they were less potent than 73 (Table 4), they were still quite active, and retained 
biological activities in the nanomolar range. The slightly reduced biological activities might be 
due to the conformational change after the introduction of the cyclopropane moiety, not the 
expected steric hindrance on the target binding caused by this moiety. Compared to analogue 73, 
the similar activities of these two cyclopropane analogues 71 and 72 suggest that the trans 
isomer of the C8-C9 double bond of FR901464 is the active species. 
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Table 4. Antiproliferative activities of 71, 72 and 73 against MCF-7 cells 
FR901464 analogues GI50 (nM) 
O
N
H
O
O O
O
MeO
N
O
O
71
 
15 
O
N
H
O
O O
O
MeO
N
O
O
72
 
10 
O
N
H
O
O O
O
MeO
N
O
O
73
 
0.38 
 
 In summary, two cyclopropane analogues, 71 and 72, were synthesized with the 
cyclopropane moiety constructed via an asymmetric Simmons-Smith reaction. Compared to 
analogue 73, these two analogues were equipotent towards MCF-7 cell lines, which implied that 
the cyclopropane moiety might not inhibit the binding to the targets. In addition, the 
cyclopropane ring also locked the compound into a trans configuration at the site of interest. The 
respectable biological activities of 71 and 72 in comparison to 73 suggest that the trans isomer is 
the active form of FR901464. 
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O
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1.2.3 Development of a concise route to synthesize a new acetal analogue of FR901464 
1.2.3.1 Introduction 
The most efficient total synthesis of FR901464 has 29 steps in total with 13 steps in the longest 
linear sequence.
1,33
 The long syntheses led to difficulties in obtaining sufficient material for 
biological testing. Following the completion of the total synthesis of FR901464 in the Koide 
group, its SAR was studied by preparing a series of analogues. Meanwhile, strategies were 
developed to synthesize simpler analogues with potent activity. During this course, acetal 
analogue 33 (Figure 4) was synthesized.
35
 Although analogue 33 was moderately potent 
compared to other analogues, the simplified left-hand acetal ring was easily accessed. 
Concurrently, if the acetyl side chain was changed to a more biologically stable morpholine-
based carbamate side chain,
35
 the potency could be improved. In the first generation synthesis of 
acetal analogues, the free amine of the acetal ring was required to protection and deprotection 
(Scheme 13),
35
 which influenced the synthetic efficacy. Therefore, I decided to synthesize acetal 
analogue 92 (Scheme 14) via a modified strategy by assembling 88and diol amine 95 first. 
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Scheme 13. The first generation synthesis of the acetal ring 
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Scheme 14. Retrosynthetic analysis of 92 
1.2.3.2 Concise synthesis of FR901464 acetal analogue 
I started the synthesis of the acetal analogue 92 by developing a concise strategy to prepare acid 
88. Previously, side chain 88 (Scheme 15) was synthesized from propargylic alcohol 15 (Scheme 
3) in 7 steps,
35
 and the stereocenter was constructed by using a CBS reduction. I realized that it 
would be more convenient to construct the cis double bond with an aldehyde
28
 (Scheme 15) and 
Ando's reagent 98.
72-77
 Therefore, carbamate 97 was assembled first by the treatment of 96 with 
CDI and morphoine. Then, 97 was treated with DIBALH to give crude 99, followed by 
olefination with Ando's reagent 98 to afford 100 with 94% Z-selectivity. However, the yield was 
only 22% over two steps. The low yield was presumably due to the high water solubility of 99. I 
was also concerned that aldehyde 99 might suffer from racemization during workup. Therefore, a 
one-pot procedure was developed, in which, without separation of aldehyde 99 from the reaction 
mixture, Ando’s reagent 98 was added immediately after the ester 97 disappeared. Pleasingly, 
ester 100 was obtained in 89% yield. Subsequent hydrolysis of ester 100 with NaOH gave 
fragment 88 in 70% total yield over three steps. 
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Scheme 15. Synthesis of 88 
 
The mechanism of this Horner-Wadsworth-Emmons reaction
78-79
 is shown in Scheme 16. 
Ando’s reagent 98 and aldehyde 99 formed two intermediates 101 and 103 in the presence of 
base (Scheme 16). Intermediate 101 was kinetically favored over 103, and irreversibly collapsed 
to Z-olefin 100 via 102. The electron-withdrawing property of aryloxy group increased the 
reactivity of the adduct 101 to Z-olefin, which consequently lowered the ratio of decomposition 
to the starting materials. Therefore, the predominant formation of Z-olefin 100 was observed.
77
 
In addition, the tert-butyl group on the ortho position could enhance the Z-selectivity of the 
reaction.
77
 The enhancement of selectivity is presumably caused by the bulkiness of the tert-
butyl group destabilizing the intermediate 102. As shown in Figure 15, the hydrogens on the tert-
butyl group are in very close vicinity.  
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Scheme 16. The mechanism of Horner–Wadsworth–Emmons reaction with Ando reagents 
 
    
Figure 15. Two-dimensional views of intermediate 102 
 
Diene intermediate 94 was prepared from 3-butenal diethyl acetal and methacrolein 
(Scheme 17).  These two compounds were coupled via a cross metathesis reaction to give enone 
106. Further treatment of 106 with the Wittig reagent resulted in fragment diene 94. Subsequent 
acetal formation between 93 and 94 afforded fragment 107 as a single diastereoisomer. The 
synthesis of analogue 92 was then accomplished by coupling 107 and 59 by using a cross 
metathesis reaction.  
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Scheme 17. Synthesis of 92  
 
In summary, the side chain 88 was prepared from commercially available (−)-ethyl L-
lactate in 3 steps. Moreover, the acetal ring was successfully formed at a late stage with 
protection and deprotection of the amino group. Acetal analogue 92 was synthesized with a new 
strategy containing a total of 20 steps, with 12 steps in the longest linear sequence. The 
antiproliferative profile of 92 is under study in the Koide laboratory. Simultaneously, a concise 
synthesis of the right fragment 59 is being developed in the laboratory.  
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EXPERIMENTAL SECTION 
General techniques. All reactions were carried out with dry, freshly distilled solvents under 
anhydrous conditions, unless otherwise noted. Tetrahydrofuran (THF) was distilled from 
sodium/benzophenone, and methylene chloride (CH2Cl2) was distilled from calcium hydride. 
Acetonitrile was dried by passing through hot silica gel. Yields refer to spectroscopically (
1
H 
NMR) homogenous materials, unless otherwise stated.  
All reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25-
mm Merck (EMD) silica gel plates (60F-254) using UV light (254 nm), anisaldehyde in ethanol, 
2.4% phosphomolybdic acid/1.4% phosphoric acid/5% sulfuric acid in H2O, or 0.2% ninhydrin 
in ethanol and heat as developing agents. TSI silica gel (230-400 mesh) was used for flash 
column chromatography.  
NMR spectra were recorded on AM300, AM500 or AM600 (Bruker) instruments and 
calibrated using a solvent peak as an internal reference. The following abbreviations are used to 
indicate the multiplicities: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. 
High-resolution mass spectra were obtained by using EBE geometry and electron impact 
ionization (EI) or a Q-TOF API-US with electrospray ionization (ESI) in the positive ion modes.
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Preparation of 47. An oven-dried, 100-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 46 (2.05 g, 8.49 mmol) and CH2Cl2 (30 mL). The solution was cooled in an ice-
water bath and NIS (2.87 g, 12.7 mmol) was added in one potion.  The resulting mixture was 
warmed to 4 °C and stirred at the same temperature for 110 h. After additional NIS (0.96 g, 4.3 
mmol) was added, the stirring was continued for 22 h at 4 °C, and saturated aqueous Na2S2O3 (2 
× 10 mL) was added. The mixture was extracted with CH2Cl2 (2 × 30 mL). The combined 
organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo. The crude residue was purified by flash chromatography (5 to 20% 
EtOAc in hexanes) on silica gel (90 mL) to afford 47 (2.02 g, 76%, dr = 6:1) as a yellow oil. 
Data for 47: Rf = 0.33 (30% EtOAc in hexanes); IR (neat): 2982, 2933, 1764 (C O), 
1711, 1419, 1384, 1369, 1306, 1246, 1170, 1106, 1029 cm
-1
; 
1
H NMR (600 MHz, 293K, CDCl3) 
δ 4.40 (dt, 1H, J = 10.2, 4.2 Hz), 3.85 (dq, 1H, J = 8.4, 6.0 Hz), 3.60 (dd, 1H, J = 8.4, 4.2 Hz), 
3.46 (dd, 1H, J = 10.2, 4.2 Hz), 3.25 (t, 1H, J = 10.2 Hz), 1.71 (s, 3H), 1.50 (s, 3H), 1.39 (d, 3H, 
J = 6.0 Hz); 
13
C NMR (150 MHz, CDCl3, 293K) δ 156.0, 95.0, 76.2, 74.9, 70.3, 29.6, 24.1, 17.4, 
6.2; HRMS (EI ) calcd. for C8H11NO3I [M–CH3]
+
 295.9784, found 295.9779. 
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Preparation of 49. A 250-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar was charged with 47 (8.90 g, 28.6 mmol), followed by EtOH 
(120 mL) and Et3N (24.1 mL, 0.172 mol). The flask was flushed with nitrogen, and charged with 
10% Pd/C (0.45 g, 1.5 mol%). The flask was then fitted with a three-way connected with a 
hydrogen balloon, and flushed with hydrogen. The resulting mixture was stirred at 23 °C for 22 h 
under hydrogen atmosphere. The mixture was filtered through celite and washed with EtOAc 
(100 mL). The filtrate was concentrated in vacuo, and the crude residue was redissolved in 
EtOAc (100 mL). The resulting solution was washed with water (2 × 20 mL), saturated aqueous 
CuSO4 (2 × 20 mL) and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated 
in vacuo. The crude residue was purified by flash chromatography (10 to 40% EtOAc in 
hexanes) on silica gel (200 mL) to afford 49 (4.7 g, 88%) as a colorless oil. 
Data for 49: Rf  = 0.49 (60% EtOAc in hexanes); IR (neat): 2983, 2934, 1759 (C O), 
1455, 1384, 1369, 1312, 1243, 1099, 1033 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 4.39 (dq, 
1H, J = 6.0, 5.0 Hz, 13-H), 3.83 (dq, 1H, J = 10.5, 6.0 Hz, 15-H), 3.42 (dd, 1H, J = 10.5, 5.0 Hz, 
14-H), 1.69 (s, 3H), 1.48 (s, 3H), 1.47 (d, 3H, J = 6.0 Hz), 1.28 (d, 3H, J = 6.0 Hz); 
13
C NMR 
(125 MHz, 293K, CDCl3) δ 156.5, 94.6, 76.2, 73.1, 71.8, 29.4, 24.1, 21.6, 17.2; HRMS (EI ) 
calcd. for C8H12NO3 [M–CH3]
+
 170.0817, found 170.0819. 
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Preparation of 50. A 50-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar and a rubber septum was charged with 49 (1.73 g, 9.32 mmol), 
THF (20 mL) and aqueous HCl (4 M, 10 mL). The resulting mixture was stirred at 23 °C for 30 
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min and then quenched with aqueous NaHCO3 (4 M, 10 mL). The organic solvent was removed 
in vacuo, and the residue was used for next step. 
Data for 50: Rf  = 0.35 (10% MeOH in CH2Cl2); IR (neat): 3645, 3368, 2958, 2923, 1740 
(C O), 1431, 1389, 1312, 1233, 1157, 1120, 1078, 1052 cm
-1
; 
1
H NMR (500 MHz, 293K, 
CDCl3) δ 6.73 (br s, 1H, NH), 4.45 (dq, 1H, J = 6.5, 6.0 Hz, 13-H), 3.69 (dq, 1H, J = 6.0, 6.0 Hz, 
15-H), 3.27 (t, 1H, J = 6.0 Hz, 14-H), 1.44 (d, 1H, J = 6.5 Hz), 1.18 (d, 1H, J = 6.0 Hz); 
13
C 
NMR (125 MHz, 293K, CDCl3) δ 160.0, 76.0, 68.9, 65.6, 21.1, 19.3; HRMS (EI ) calcd. for 
C6H12NO3 [M]
+
 146.0817, found 146.0816. 
 
HN
OO
KOH; Boc2O
OH OH
NHBoc
37 %
(3 steps)
50 52
16 13''13
14
15
HO
 
Preparation of 52 . A 50-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar and a condenser was charged with crude 50 (1.36g, 9.32 mmol) 
in water (10 mL), a solution of KOH (4 M, 10 mL) and dioxane (20 mL). The mixture was 
heated to reflux in an oil bath for 1h. After being cooled to 23 °C, Boc2O (6.20 g, 28.4 mmol) 
was added. The mixture was then stirred at 23 °C for 20 h, and extracted with EtOAc (3 × 30 
mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (30 to 60% EtOAc in hexanes) on silica gel (100 mL) to afford 52 (0.76 g, 37% 
for 3 steps) as a colorless oil. 
Data for 52: Rf  = 0.38 (10% MeOH in CH2Cl2); IR (neat): 3409, 2977, 2934, 1692 
(C O), 1505, 1465, 1393, 1367, 1250, 1169, 1121, 1069 cm
-1
; 
1
H NMR (300 MHz, 293K, 
CDCl3) δ 5.29 (br d, 1H, J = 9.6 Hz, NH), 4.08 (qd, 2H, J = 6.3, 1.5 Hz, 13- or 15-H), 3.35 (d, 
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1H, J = 9.9 Hz, 14-H), 1.44 (s, 9H), 1.17 (d, 6H, J = 6.3 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) 
δ 157.1, 79.3, 71.1, 57.8, 28.3, 20.3; HRMS (EI ) calcd. for C10H21NO4 [M]
+
 219.1471, found 
219.1470. 
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Preparation of 53. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 52 (0.670 g, 3.47 mmol) and CH2Cl2 (12 mL). The solution was cooled in an ice-
water bath, and then 3-butenal diethyl acetal (0.71 mL, 4.1 mmol) and CSA (81 mg, 0.35 mmol) 
were added sequentially. The mixture was warmed to 4 °C and stirred at the same temperature 
for 64 h. Et3N (0.10 mL) was added, and the solvent was removed in vacuo. The crude residue 
was purified by flash chromatography (2 to 8% EtOAc in hexanes) on silica gel (25 mL) to 
afford the acetal 53 (616 mg, 66%) as a colorless oil. 
Data for 53: Rf  = 0.58 (30% EtOAc in hexanes); IR (neat): 3454, 2981, 1644 (C O), 
1502, 1365, 1312, 1238, 1167, 1133, 1082, 1019 cm
-1
; 
1
H NMR (300 MHz, 293K, CDCl3) δ 
5.89–5.75 (m, 1H, 9-H), 5.16–5.08 (m, 1H, 9'-H), 4.95 (br d, 1H, J = 10.2 Hz, NH), 3.84 (qd, 
2H, J = 6.6, 1.5 Hz, 13- or 15-H), 3.39 (dt, 1H, J = 10.2, 1.5 Hz, 14-H), 2.40–2.36 (m, 2H, 10-
H), 1.46 (s, 9H), 1.19 (d, 6H, J = 6.3 Hz); 
13
C NMR (75 MHz, CDCl3, 293K) δ 156.5, 132.6, 
117.6, 101.6, 79.2, 75.5, 51.6, 39.3, 28.3, 17.3; HRMS (EI ) calcd. for C14H25NO4 [M]
+
 
271.1784, found 271.1771. 
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Preparation of 54. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar and a rubber septum was charged with 53 (0.23 
g, 0.84 mmol) and CH2Cl2 (7.2 mL). The mixture was cooled in an ice-water bath, and TFA (0.8 
mL) was added dropwise via a syringe. The resulting mixture was warmed to 23 °C and stirred at 
the same temperature for 3 h. After concentration of the mixture, heptanes (5 mL) was added and 
removed in vacuo. The residue was dissolved in MeCN (4 mL) and used in the next step.  
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Preparation of 55. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 2 (0.220 g, 1.39 mmol), MeCN (4 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (0.528 g, 1.39 mmol) followed by N, N′-
diisopropylethylamine (0.810 mL, 4.64 mmol). The resulting mixture was stirred at 23 °C for 5 
min, and then cannulated to a solution of 54 in MeCN (4 mL). After 10 min at 23 °C, saturated 
aqueous NH4Cl (10 mL) was added, and the mixture was extracted with EtOAc (3 × 20 mL). The 
combined organic layers were washed with brine (20 mL), dried over anhydrous Na2SO4, filtered 
and concentrated in vacuo. The crude residue was purified by flash chromatography (15 to 40% 
EtOAc in hexanes) on silica gel (12 mL) to afford 55 (180 mg, 69%) as a colorless oil. 
Data for 55: Rf = 0.41 (40% EtOAc in hexanes); IR (neat): 3324, 2981, 2933, 2859, 1736 
(C=O), 1671 (C=O), 1641, 1512, 1439, 1371, 1341, 1307, 1242, 1177, 1123, 1046 cm
-1; [α]D
22
 -
 41 
12.0 (c 0.94, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 6.58 (br d, 1H, J = 9.3 Hz, NH), 6.16 
(dq, 1H, J = 6.6, 6.6 Hz, 4'-H), 5.93–5.75 (m, 3H, 9-, 2'- and 3'-H), 5.16–5.07 (m, 2H, 9'-H), 4.66 
(t, 1H, J = 5.4 Hz, 11-H), 3.93–3.83 (m, 3H, 13-, 14- and 15-H), 2.41–2.37 (m, 2H, 10-H), 2.04 
(s, 3H, 2''-H), 1.37 (d, 3H, J = 6.3 Hz), 1.19 (d, 3H, J = 6.3 Hz), 1.17 (d, 3H, J = 6.3 Hz); 
13
C 
NMR (75 MHz, 293K, CDCl3) δ 170.8, 166.0, 142.8, 132.8, 123.1, 117.9, 102.0, 75.6, 75.4, 
69.1, 50.4, 39.5, 21.4, 20.2, 17.7, 17.6; HRMS (EI ) calcd. for C16H25NO5 [M]
+
 311.1733, found 
311.1736. 
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Preparation of 57. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 55 (0.14 g, 0.44 mmol) followed by methacrolein (1.10 mL, 13.6 mmol) and 56 
(4.0 mg, 5.0 μmol). The resulting mixture was stirred at 23 °C for 23 h, and the excess 
methacrolein was removed in vacuo. The residue was purified by flash chromatography (30 to 
50% EtOAc in hexanes) on silica gel (8 mL) to afford 57 (85 mg, 84%) as a white solid. 
Data for 57: Rf = 0.26 (60% EtOAc in hexanes); IR (neat): 3361, 2982, 2935, 2867, 1735 
(C=O), 1674 (C=O), 1643 (C O), 1519, 1417, 1372, 1340, 1308, 1243, 1175, 1124, 1047 cm
-1
; 
[α]D
22
 -11.9 (c 0.73, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 9.45 (s, 1H, 8'-H), 6.71 (br d, 
1H, J = 9.6 Hz, NH), 6.61–6.56 (m, 1H, 9-H), 6.12–6.02 (m, 1H, 4'-H), 5.90–5.81 (m, 2H, 2'- 
and 3'-H), 4.81 (t, 1H, J = 5.4 Hz, 11-H), 3.98–3.09 (m, 3H, 13-, 14- and 15-H), 2.74–2.70 (m, 
2H, 10-H), 2.06 (s, 3H, 2''-H), 1.76 (d, 3H, J = 1.2 Hz, 19-H), 1.38 (d, 3H, J = 6.6 Hz), 1.20 (d, 
 42 
3H, J = 6.6 Hz), 1.18 (d, 3H, J = 6.6 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 195.2, 171.0, 
166.2, 147.7, 141.6, 141.4, 123.5, 100.5, 75.8, 75.6, 69.1, 50.3, 34.8, 21.4, 20.2, 17.7, 17.6, 9.7; 
HRMS (ESI ) calcd. for C18H27NO6Na [M Na]
+
 376.1736, found 376.1733. 
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Preparation of 58. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with methyltriphenylphosphonium bromide (0.35 g, 0.97 mmol) and THF (3 mL). The 
mixture was cooled in an ice-water bath and a solution of KO
t
Bu in THF (0.85 mL, 1M, 0.85 
mmol) was added via a syringe. After 30 min at 0 °C, aldehyde 57 (86 mg, 0.24 mmol) in THF 
(1 mL) was added via cannula and rinsed with additional THF (1 mL). The reaction mixture was 
stirred at 0 °C for 20 min, and saturated aqueous NH4Cl (2 mL) was added. After removal of 
THF, the mixture was extracted with EtOAc (3 × 15 mL). The combined organic layers were 
washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude residue was purified by flash chromatography (10 to 30% EtOAc in hexanes) on silica 
gel (8 mL) to afford 58 (57 mg, 67%) as a colorless oil. 
Data for 58: Rf = 0.60 (60% EtOAc in hexanes); IR (neat): 3331, 2981, 2933, 2864, 1737 
(C=O), 1672 (C=O), 1642, 1512, 1443, 1371, 1340, 1307, 1242, 1175, 1125, 1047 cm
-1; [α]D
22
 -
13.5 (c 0.55, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 6.53 (br d, 1H, J = 9.6 Hz, NH), 6.35 
(dd, 1H, J = 17.4, 10.8 Hz, 7-H), 6.21–6.09 (m, 1H, 4'-H), 5.92–5.82 (m, 2H, 2' and 3'-H), 5.53 
(t, 1H, J = 7.2 Hz, 9-H), 5.10 (d, 1H, J = 17.4 Hz, 7'-H), 4.96 (d, 1H, J = 10.8 Hz, 7'-H), 4.67 (t, 
1H, J = 5.4 Hz, 11-H), 3.94–3.86 (m, 3H, 13-, 14- and 15-H), 2.50 (t, 2H, J = 6.3 Hz, 10-H), 
 43 
2.05 (s, 3H, 2''-H), 1.75 (d, 3H, J = 0.9 Hz, 19-H), 1.38 (d, 3H, J = 6.3 Hz), 1.18 (d, 3H, J = 5.4 
Hz), 1.16 (d, 3H, J = 5.4 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 170.6, 165.8, 142.3, 141.2, 
136.3, 126.0, 123.0, 111.4, 101.8, 75.4, 75.3, 68.9, 50.2, 34.0, 21.2, 20.0, 17.6, 17.4, 12.0; 
HRMS (EI ) calcd. for C19H29NO5 [M]
+
 351.2046, found 351.2028. 
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Preparation of 41. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar and a rubber septum was charged with 58 (27 
mg, 78 μmol), 59 (23 mg, 0.13 mmol), DCE (0.5 mL) and 56 (2.6 mg, 3.8 μmol). The mixture 
was heated to 40 °C and stirred for 4 h at the same temperature. Additional 56 (2.6 mg, 3.8 
μmol) was added. After 10 total hours, the mixture was concentrated in vacuo. The residue was 
purified by flash chromatography (10 to 80% EtOAc in hexanes) on silica gel (5 mL) to afford 
41 (6.5 mg, 16%) as a solid, and a mixture of 58 and 59 (23 mg). 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar and a rubber septum was charged with recovered 58 and 59 (23 mg) 
followed by DCE (0.3 mL) and 56 (2.6 mg, 3.8 μmol). The reaction mixture was heated to 40 °C. 
After 23 h at the same temperature, the mixture was concentrated in vacuo. The residue was 
purified by flash chromatography (10 to 80% EtOAc in hexanes) on silica gel (4 mL) to afford 
41 (2.5 mg, 6%). The combined yield of 41 after one cycle was 9.0 mg (22%). 41 was further 
purified by preparative TLC, and afforded as a white solid. 
 44 
Data for 41: Rf  = 0.30 (70% EtOAc in hexanes); IR (neat): 3732, 3584, 2920, 2851, 1733 
(C O), 1670 (C O), 1649, 1557, 1519, 1456, 1372, 1242, 1123, 1049 cm
-1; [α]D
22
 +9.1 (c 0.10, 
CHCl3); 
1
H NMR (500 MHz, 293K, CD2Cl2) δ 6.35 (d, 1H, J = 15.5 Hz, 7-H), 6.31 (br d, 1H, J 
= 10.0 Hz, NH), 6.21–6.16 (m, 1H, 4'-H), 5.91 (dd, 1H, J = 11.5, 8.0 Hz, 3'-H), 5.84 (dd, 1H, J = 
11.5, 1.0 Hz, 2'-H), 5.66 (dd, 1H, J = 15.5, 7.0 Hz, 6-H), 5.53 (t, 1H, J = 7.5 Hz, 9-H), 4.66 (t, 
1H, J = 5.5 Hz, 11-H), 3.91–3.87 (m, 3H), 3.83 (m, 1H), 3.48 (t, 1H, J = 10.0 Hz, 4-H), 2.96 (d, 
1H, J = 4.5 Hz, 18-H), 2.90–2.44 (m, 2H, 10-H), 2.46 (d, 1H, J = 4.5 Hz, 18-H), 2.16 (d, 1H, J = 
14.0 Hz, 2-H), 2.02 (s, 3H, 2''-H), 1.77 (s, 3H, 19-H), 1.61 (d, 1H, J = 11.5 Hz, 4-OH), 1.40 (d, 
1H, J = 14.0 Hz, 2-H), 1.36 (s, 3H), 1.34 (d, 3H, J = 6.5 Hz), 1.23 (s, 3H), 1.14 (d, 3H, J = 6.5 
Hz), 1.12 (d, 3H, J = 6.5 Hz); 
13
C NMR (125 MHz, 293K, CD2Cl2) δ 170.4, 165.5, 142.9, 137.2, 
135.3, 126.5, 125.8, 122.6, 101.7, 75.3, 75.2, 74.5, 72.7, 68.6, 68.2, 57.4, 50.0, 47.4, 42.7, 34.0, 
31.6, 30.7, 24.6, 22.7, 21.0, 19.8, 17.2; HRMS (EI ) calcd. for C27H41NO8 [M]
+
 507.2832, found 
507.2851. 
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Preparation of 62. A 100-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar was charged with 2-amino-1,3-propanediol (0.94 g, 10 mmol), 
THF (18 mL) and water (12 mL). The mixture was cooled in an ice-water bath, and Boc2O (2.36 
g, 10.8 mmol) and NaHCO3 (1.73 g, 20.6 mmol) were added to the mixture sequentially. The 
resulting mixture was warmed to 23 °C and stirred at the same temperature for 18 h. The mixture 
was extracted with EtOAc (4 × 20 mL). The combined organic layers were washed with brine 
(30 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue 
 45 
was purified by flash chromatography (2 to 10% MeOH in CH2Cl2) on silica gel (100 mL) to 
afford 62 (1.70 g, 86%) as a colorless oil. 
Data for 62. See Benoist, E.; Loussouarn, A.; Remaud, P.; Chatal, J. F.; Gestin, J. F. 
Synthesis 1998, 1113-1118. 
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Preparation of 63. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 62 (0.737 g, 3.86 mmol), CH2Cl2 (15 mL) and THF (5 mL). The solution was 
cooled in an ice-water bath, and 3-butenal diethyl acetal (0.98 mL, 5.8 mmol) and CSA (91 mg, 
0.39 mmol) were added. The mixture was stirred at 0 °C for 70 h and then warmed to 23 °C. 
After additional 20 h, Et3N (0.10 mL) was added, and the solvent was removed in vacuo. The 
crude residue was purified by flash chromatography (5 to 20% EtOAc in hexanes) on silica gel 
(50 mL) to afford 63 (647 mg, 72%, dr = 1.5:1.0) as a colorless oil. Its trans diastereoisomer was 
partially separated by recrystallization. After recrystallization, the diastereoisomer ratio was 5:1. 
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Preparation of 61. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar and a rubber septum was charged with 63 (345 
mg, 1.42 mmol) and CH2Cl2 (9 mL). The solution was cooled in ice-water bath, and TFA (1 mL) 
 46 
was added dropwise via a syringe. The resulting mixture was warmed to 23 °C and stirred for 6.5 
h. After concentration of the mixture, heptane (7 mL) was added and removed in vacuo. The 
residue was dissolved in MeCN (6 mL) and used in the next step.  
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Preparation of 64. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 2 (0.270 g, 1.70 mmol), CH3CN (6 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (0.646 g, 1.70 mmol), followed by N, N′-
diisopropylethylamine (0.990 mL, 5.68 mmol) via a syringe. The resulting mixture was stirred at 
23 °C for 5 min and then added to the solution of 61 in MeCN prepared in last step. The resulting 
pale yellow solution was stirred 23 °C for 20 min. Water (7 mL) was added, and the mixture was 
extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 
mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue was 
purified by flash chromatography (10 to 50% EtOAc in hexanes) on silica gel (30 mL) to afford 
64 (265 mg, 66%) as a colorless oil. 
Data for 64: Rf  = 0.28 (50% EtOAc in hexanes); IR (neat): 3417, 2978, 2930, 2859, 1732 
(C O), 1667 (C O), 1640, 1528, 1452, 1372, 1244, 1145, 1119, 1073, 1048, 1013 cm
-1; [α]D
22
 
+3.7 (c 0.95, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 7.20 (br d, 1H, J = 6.6 Hz, NH), 6.14 
(dq, 1H, J = 6.6, 6.6 Hz, 4'-H), 5.91–5.75 (m, 3H, 9-, 2'- and 3'-H), 5.18–5.09 (m, 2H, 9'-H), 4.65 
(t, 1H, J = 5.1 Hz, 11-H), 4.05–3.92 (m, 5H, 13-, 14- and 15-H), 2.45–2.40 (m, 2H, 10-H), 2.06 
(s, 3H, 2''-H), 1.38 (d, 3H, J = 6.3 Hz, 5'-H); 
13
C NMR (75 MHz, 293K, CDCl3) δ 171.0, 165.1, 
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142.5, 132.4, 123.6, 118.3, 102.3, 70.5, 69.1, 44.1, 39.8, 21.5, 20.4; HRMS (EI ) calcd. for 
C14H21NO5 [M]
+
 283.1420, found 283.1410. 
 
O
O
N
H
O
O
O
O
N
H
O
O OO
N N MesMes
Ru
O
Cl
Cl
NO2
60%
64 6556
O O
1314
15
10
11 9
8
4'
3'
2'
5'2''
19
8'
 
Preparation of 65. A 10-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar, a nitrogen inlet and a rubber septum was charged with 64 (0.27 
g, 0.95 mmol), methacrolein (1.2 mL, 14 mmol) and 56 (6.3 mg, 9.4 μmol). The resulting 
mixture was stirred 23 °C for 22 h, and additional 56 (6.3 mg, 9.4 μmol) was added. The stirring 
was continued for 13 h and the mixture was concentrated in vacuo. The residue was purified by 
flash chromatography (30 to 80% EtOAc in hexanes) on silica gel (15 mL) to afford 65 (185 mg, 
60%) as a colorless oil. 
Data for 65: Rf  = 0.25 (70% EtOAc in hexanes); IR (neat): 3425, 2977, 2929, 2858, 1730 
(C O), 1668 (C O), 1641(C O), 1529, 1373, 1246, 1129, 1048, 1020 cm
-1; [α]D
22
 +2.7 (c 1.3, 
CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 9.44 (s, 1H, 7-H), 7.42 (br d, 1H, J = 7.5 Hz, NH), 
6.59 (dq, 1H, J = 6.9, 0.9 Hz, 9-H), 6.10–6.00 (m, 1H, 4'-H), 5.83 (d, 2H, J = 3.3 Hz, 2'- and 3'-
H), 4.79 (t, 1H, J = 5.4 Hz, 11-H), 4.07–3.06 (m, 5H, 13-, 14- and 15-H), 2.71 (t, 2H, J = 5.4 Hz, 
10-H), 2.06 (s, 3H, 2''-H), 1.76 (s, 3H, 19-H), 1.37 (d, 3H, J = 6.3 Hz, 5'-H); 
13
C NMR (75 MHz, 
293K, CDCl3) δ 194.8, 170.9, 164.9, 146.9, 141.3, 141.1, 123.7, 100.7, 70.2, 68.8, 43.6, 34.6, 
21.2, 20.1, 9.4; HRMS (ESI ) calcd. for C16H23NO6Na [M+Na]
+
 348.1423, found 348.1438. 
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Preparation of 66. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with methyltriphenylphosphonium bromide (0.803 g, 2.25 mmol) and THF (8 mL). The 
solution was cooled in an ice-water bath, and a solution of KO
t
Bu in THF (1M, 1.90 mL, 1.90 
mmol) was added via a syringe. The mixture was stirred for 10 min at the same temperature. A 
solution of 65 (0.183 g, 0.566 mmol) in THF (7 mL) was added to the mixture via cannula, and 
the stirring was continued for 10 min. H2O (5 mL) was added. After removal of THF, the 
mixture was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with 
brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude 
residue was purified by flash chromatography (10 to 50% EtOAc in hexanes) on silica gel (20 
mL) to afford 66 (124 mg, 69%) as a colorless oil. 
Data for 66: Rf  = 0.36 (50% EtOAc in hexanes); IR (neat): 3358, 2978, 2933, 2861, 1735 
(C O), 1668 (C O), 1639, 1526, 1451, 1419, 1372, 1244, 1157, 1131, 1049, 1011 cm
-1; [α]D
23
 -
15.7 (c 1.3, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 7.24 (br d, 1H, J = 8.1 Hz, NH), 6.39 
(dd, 1H, J = 17.4, 10.8 Hz, 7-H), 6.13 (dq, 1H, J = 6.6, 6.6 Hz, 4'-H), 5.90–5.79 (m, 2H, 2'- and 
3'-H2), 5.52 (t, 1H, J = 7.2 Hz, 9-H), 5.13 (d, 1H, J = 17.4 Hz, 7'-H), 4.98 (d, 1H, J = 10.5 Hz, 7'-
H), 4.64 (t, 1H, J = 5.1 Hz, 11-H), 4.04–3.93 (m, 5H, 13-, 14- and 15-H), 2.52 (t, 2H, J = 6.3 Hz, 
10-H), 2.06 (s, 3H, 2''-H), 1.76 (s, 3H, 19-H), 1.38 (d, 3H, J = 6.6 Hz, 5'-H); 
13
C NMR (75 MHz, 
293K, CDCl3) δ 170.7, 164.8, 141.9, 141.1, 136.5, 125.4, 123.4, 111.5, 102.1, 70.2, 68.8, 43.8, 
34.1, 21.2, 20.1, 11.9; HRMS (ESI ) calcd. for C17H25NO5Na [M Na]
+
 346.1630, found 
346.1654. 
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Preparation of 42. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 66 (55 mg, 0.17 mmol), 56 (25 mg, 0.14 mmol), DCE (0.5 mL), benzoquinone (3.7 
mg, 34 μmol) and 56 (5.7 mg, 8.5 μmol). The mixture was heated to 40 oC and stirred at the 
same temperature for 4 h, and additional 56 (5.7 mg, 8.5 μmol) was added to the mixture. The 
stirring was continued at the same temperature for 18 h, and the mixture was concentrated in 
vacuo. The residue was purified by flash chromatography (10 to 80% EtOAc in hexanes) on 
silica gel (12 mL) to afford 42 (15 mg, 18%) as a solid, and a mixture of 66 and 59 (74 mg). 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with recovered 66 and 
59 (74 mg), DCE (0.3 mL) and 56 (6.2 mg, 9.2 μmol). The mixture was heated to 40 oC and 
stirred at the same temperature for 22 h. The mixture was concentrated in vacuo. The residue was 
purified by flash chromatography (10 to 80% EtOAc in hexanes) on silica gel (10 mL) to afford 
42 (7 mg, 8%). The combined yield of 42 after one cycle is 22 mg (26%). 42 was further purified 
by preparative TLC, and afforded as a white solid.  
Data for 42: Rf  = 0.15 (70% EtOAc in hexanes); IR (neat): 3341, 1973, 2923, 2856, 1734 
(C O), 1668 (C O), 1638, 1526, 1372, 1243, 1129, 1049, 1012 cm
-1; [α]D
23
 +13.9 (c 0.77, 
CHCl3); 
1
H NMR (600 MHz, 293K, CD2Cl2) δ 7.02 (br d, 1H, J = 9.1 Hz, NH), 6.34 (d, 1H, J = 
15.6 Hz, 7-H), 6.17 (m, 1H, 4'-H), 5.89 (dd, 1H, J = 12.0, 9.8 Hz, 3'-H), 5.80 (dd, 1H, J = 12.0, 
1.2 Hz, 2'-H), 5.65 (dd, 1H, J = 15.6, 6.6 Hz, 6-H), 5.52 (t, 1H, J = 7.2 Hz, 9-H), 4.62 (t, 1H, J = 
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4.8 Hz, 11-H), 3.97–3.90 (m, 6H, 5-, 13-, 14- and 15-H), 3.48 (t, 1H, J = 10.2 Hz, 4-H), 2.96 (d, 
1H, J = 4.2 Hz, 18-H), 2.47 (m, 2H, 10-H), 2.46 (d, 1H, J = 4.2 Hz, 18-H), 2.02 (s, 3H, 2''-Me), 
1.76 (s, 3H, 19-Me), 1.61 (d, 1H, J = 10.2 Hz, 4-OH), 1.35 (s, 3H, 17-H), 1.34 (d, 3H, J = 6.6 Hz, 
5'-H), 1.23 (s, 3H, 17'-H); 
13
C NMR (150 MHz, 293K, CD2Cl2) δ 170.5, 164.5, 142.7, 137.1, 
135.5, 126.1, 125.9, 122.9, 102.0, 74.5, 72.6, 70.1, 68.5, 68.2, 57.4, 47.4, 43.8, 42.7, 34.1, 30.7, 
29.7, 23.3, 21.0, 19.8, 12.4; HRMS (ESI ) calcd. for C25H37NO8Na [M Na]
+
 502.2417, found 
502.2382. 
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Preparation of 75. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 17 (0.280 g, 1.04 mmol), methacrolein (1.70 mL, 20.8 mmol) and 56 (21 mg, 31 
μmol). The resulting mixture was stirred at 23 °C for 43 h, and the excess methacrolein was 
removed in vacuo. The residue was purified by flash chromatography (5 to 30% EtOAc in 
hexanes) on silica gel (15 mL) to afford 75 (85 mg, 84%) as a pale yellow liquid. 
Data for 75: Rf = 0.26 (30% EtOAc in hexanes); IR (neat): 3461, 2976, 2932, 1714 
(C O), 1689 (C O), 1646, 1497, 1389, 1365, 1345, 1315, 1237, 1168, 1064 cm
-1; [α]D
21
  -24.0 (c 
1.01, CHCl3); 
1
H NMR (300 MHz, 293K, CDCl3) δ 9.43 (s, 1H, 7-H), 6.58–6.53 (m, 1H, 9-H), 
4.73 (br d, 1H, J = 9.3 Hz, NH), 3.66–3.59 (m, 3H, 11-, 14- and 16-H), 2.62–2.36 (m, 2H, 10-H), 
2.02–1.92 (m, 2H, 13-H), 1.77 (s, 4H, 12- and 19-H), 1.45 (s, 9H), 1.17 (d, 3H, J = 6.3 Hz), 1.08 
(d, 3H, J = 7.2 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 195.3, 156.0, 150.8, 140.8, 79.9, 79.4, 
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48.4, 36.2, 33.1, 29.8, 28.7, 17.9, 15.3, 9.7; HRMS (EI ) calcd. for C17H29NO4 [M]
+
 311.2097, 
found 311.2100. 
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Preparation of 74. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 75 (65 mg, 0.21 mmol) and CH2Cl2 (2.0 mL). The solution was cooled in a dry ice-
acetone bath and then DIBALH (0.25 mL, 1 M, 0.25 mmol) was added dropwise via a syringe. 
After 10 min at -78 °C, the reaction was quenched with a solution of potassium sodium tartrate 
(1 M, 4 mL) at the same temperature. The resulting mixture was warmed to 23 °C, stirred at the 
same temperature for 20 min, and extracted with EtOAc (3 × 10 mL). The combined organic 
layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated 
in vacuo. The crude residue was purified by flash chromatography (10 to 30% EtOAc in 
hexanes) on silica gel (12 mL) to afford 74 (64.0 mg, 98%) as a colorless oil. 
Data for 74: Rf = 0.35 (60% EtOAc in hexanes); IR (neat): 3458, 2976, 2931, 1715 
(C O), 1499, 1390, 1366, 1238, 1169, 1060 cm
-1; [α]D
22
 -4.9 (c 1.0, CHCl3); 
1
H NMR (300 
MHz, 293K, CDCl3) δ 5.42 (ddd, 1H, J = 7.2, 7.2, 0.9 Hz, 9-H), 4.76 (d, 1H, J = 9.3 Hz, NH), 
4.02 (s, 2H, 7-H), 3.65–3.55 (m, 2H), 3.49 (ddd, 1H, J = 7.2, 7.2, 2.7 Hz), 2.34–2.10 (m, 2H, 10-
H), 1.97–1.85 (m, 2H, 13-H), 1.80–1.75 (m, 1H, 12-H), 1.69 (s, 3H, 19-H), 1.45 (s, 9H), 1.16 (d, 
3H, J = 6.3 Hz), 1.03 (d, 3H, J = 7.5 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 156.1, 136.8, 
121.8, 81.0, 79.2, 69.0, 48.6, 36.3, 31.6, 29.2, 28.7, 18.0, 15.2, 14.2; HRMS (EI ) calcd. for 
C17H31NO4 [M]
+
 313.2253, found 313.2242. 
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Preparation of 78. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with CH2Cl2 (5.0 mL) and diethylzinc (3.40 mL, 1.95 mmol). The mixture was cooled in 
ice-water bath and then diiodomethane (0.220 mL, 2.73 mmol) was added dropwise via a 
syringe. The resulting mixture was stirred at 0 °C for 10 min. A mixed solution of (S,S)-
dioxaborolane 76 (0.212 g, 0.785 mmol) and 74 (0.123 g, 0.392 mmol) in CH2Cl2 (5.0 mL) was 
added via cannula. The resulting mixture was warmed to 23 °C and stirred at the same 
temperature for 1 h. Saturated aqueous NH4Cl (5 mL), and the mixture was extracted with 
EtOAc (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
chromatography (10 to 50% EtOAc in hexanes) on silica gel (15 mL) to afford 78 (91.2 mg, 
70%, dr = 10.5:1) as a colorless oil. 
Data for 78: Rf = 0.35 (60% EtOAc in hexanes); IR (neat): 3458, 2975, 2931, 1716 
(C O), 1498, 1457, 1390, 1365, 1344, 1315, 1235, 1170, 1058 cm
-1
; 
1
H NMR (500 MHz, 293K, 
CDCl3) δ 4.78 (br d, 1H, J = 9.5 Hz, NH), 3.63 (dq, 1H, J = 6.5, 2.0 Hz), 3.58–3.51 (m, 2H), 
3.39 (d, 1H, J = 10.5 Hz, 7-H), 3.22 (d, 1H, J = 10.5 Hz, 7-H), 1.91 (t, 2H, J = 3.5 Hz), 1.78–
1.75 (m, 1H), 1.65–1.59 (m, 1H), 1.43 (s, 9H); 1.29–1.24 (m, 1H), 1.15 (d, 3H, J = 6.0 Hz), 1.00 
(d, 3H, J = 7.5 Hz), 0.70–0.65 (m, 1H), 0.56 (dd, 1H, J = 9.0, 4.5 Hz), 0.01 (dd, 1H, J = 5.0, 5.0 
Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 156.1, 81.7, 79.3, 76.6, 72.7, 48.6, 36.4, 32.4, 29.7, 
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28.6, 22.4, 18.9, 17.9, 16.8, 16.1, 15.6, 15.5; MS (ESI+) m/z 233 [M – H2NBoc + Na]
+
; HRMS 
(ESI ) calcd. for C18H23NO6Na [M Na]
+
 350.2307, found 350.2276. 
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Preparation of 81. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 78 (73 mg, 0.22 mmol) and CH2Cl2 (1.5 mL). The solution was cooled in ice-water 
bath. A solution of TFA in CH2Cl2 (1:4 v/v, 1.5 mL) was added via a syringe. Then the reaction 
mixture was warmed to 23 °C and stirred for 2 h. After concentration of the mixture, heptanes (4 
mL) was added and removed in vacuo. The residue was dissolved in MeCN (2 mL) and used in 
the next step.  
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Preparation of 82. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 2 (42 mg, 0.26 mmol), MeCN (2 mL) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (85 mg, 0.22 mmol), followed by N, N′-
diisopropylethylamine (0.16 mL, 0.89 mmol). The resulting mixture was added to a solution of 
81 in MeCN (2 mL) and rinsed with additional MeCN (1 mL). After 10 min at 23 °C, saturated 
aqueous NH4Cl (2 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The 
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combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. The crude residue was purified by flash chromatography (30 to 60% 
EtOAc in hexanes) on silica gel (12 mL) to afford 82 (39.5 mg, 48%) as a colorless oil. 
Data for 82: Rf = 0.21 (70% EtOAc in hexanes); IR (neat): 3357, 2931, 1737 (C O), 
1667 (C O), 1629, 1518, 1455, 1374, 1243, 1146, 1050 cm
-1
; 
1
H NMR (500 MHz, 293K, 
CDCl3) δ 6.24 (dq, 1H, J = 6.5 Hz, 4'-H), 6.10 (br d, 1H, J = 9.0 Hz, NH), 5.86 (dd, 1H, J = 11.5, 
7.5 Hz, 3'-H), 5.72 (dd, 1H, J = 11.5, 1.0 Hz, 2'-H), 3.95 (dddd, 1H, J = 9.0, 5.5, 2.5, 2.5 Hz), 
3.70 (qd, 1H, J = 6.5, 2.5 Hz), 3.58 (ddd, 1H, J = 8.0, 5.0, 2.5 Hz), 3.41 (d, 1H, J = 10.5 Hz, 7-
H), 3.24 (d, 1H, J = 10.5 Hz, 7-H), 2.04 (s, 3H, 2''-H), 1.98 (t, 2H, J = 3.5 Hz), 1.84–1.79 (m, 
1H), 1.63 (ddd, 1H, J = 14.5, 8.6, 6.5 Hz), 1.39 (d, 3H, J = 6.5 Hz), 1.32–1.27 (m, 1H), 1.25 (s, 
3H), 1.16 (d, 3H, J = 6.5 Hz), 1.01 (d, 3H, J = 7.0 Hz), 0.73–0.67 (m, 1H), 0.57 (dd, 1H, J = 9.0, 
4.5 Hz), 0.03 (dd, 1H, J = 4.5, 4.5 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 170.6, 164.3, 143.7, 
122.8, 81.9, 76.2, 72.7, 69.2, 47.4, 36.2, 32.4, 29.9, 29.7, 22.4, 21.5, 20.2, 18.9, 18.1, 16.9, 16.1; 
HRMS (ESI ) calcd. for C20H33NO5Na [M Na]
+
 390.2256, found 390.2233. 
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Preparation of 83. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with Dess-Martin periodinane (77 mg, 0.18 mol) and CH2Cl2 (3.0 mL). The resulting 
mixture was cooled in an ice-water bath, and 82 (33 mg, 90 mol) was added. The mixture was 
stirred at 0 °C for 1.5 h. Saturated aqueous NaHCO3 (3 mL) and Na2SO3 (220 mg) were added, 
and the stirring was continued for 30 min. The mixture was extracted with EtOAc (3 × 10 mL). 
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The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (20 
to 50% EtOAc in hexanes) on silica gel (7 mL) to afford 83 (23 mg, 70%) as a colorless oil. 
Data for 83: Rf = 0.31 (60% EtOAc in hexanes); IR (neat): 3357, 2973, 2932, 1735 
(C O), 1702 (C O), 1669 (C O), 1637, 1519, 1456, 1371, 1317, 1245, 1123, 1049 cm
-1
; 
1
H 
NMR (500 MHz, 293K, CDCl3) δ 8.68 (s, 1H, 7-H), 6.27–6.22 (m, 1H, J = 8.0, 6.5, 1.5 Hz, 4'-
H), 6.02 (br d, 1H, J = 9.0 Hz, NH), 5.89 (dd, 1H, J = 11.5, 8.0 Hz, 3'-H), 5.72 (d, 1H, J = 11.5, 
1.0 Hz, 2'-H), 3.98–3.96 (m, 1H), 3.69 (qd, 1H, J = 6.5, 2.5 Hz), 3.59 (ddd, 1H, J = 8.5, 5.5, 3.0 
Hz), 2.05 (s, 3H, 2'-H), 2.00–1.98 (m, 2H), 1.82–1.77 (m, 2H), 1.52–1.46 (m, 1H), 1.40 (d, 3H, J 
= 6.5 Hz), 1.37–1.29 (m, 2H), 1.26 (s, 3H), 1.16 (d, 3H, J = 6.5 Hz), 1.13 (d, 3H, J = 7.5 Hz), 
0.66 (dd, 1H, J = 6.5, 4.5 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 202.7, 170.6, 165.1, 143.7, 
122.8, 81.0, 76.3, 69.1, 47.3, 36.2, 32.1, 31.9, 29.8, 22.1, 21.5, 20.2, 20.1, 18.0, 15.5, 11.7; 
HRMS (EI ) calcd. for C20H31NO5 [M]
+
 365.2202, found 365.2199. 
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Preparation of 84. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with methyltriphenylphosphonium bromide (0.18 g, 0.49 mmol) and THF (2 mL). The 
resulting mixture was cooled in an ice-water bath and then a solution of KO
t
Bu in THF (0.41 
mL, 1 M, 0.41 mmol) was added. The mixture was stirred at 0 °C for 20 min, aldehyde 83 (31 
mg, 81 mol) in THF (1 mL) was added via cannula and rinsed with THF (1 mL). After 10 min, 
H2O (2 mL) was added. After removal of THF, the mixture was extracted with EtOAc (2 × 15 
 56 
mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
chromatography (5 to 30% EtOAc in hexanes) on silica gel (5 mL) to afford 84 (23.6 mg, 80%) 
as a colorless oil. 
Data for 84: Rf = 0.47 (50% EtOAc in hexanes); IR (neat): 3362, 2925, 2853, 1738 
(C O), 1668 (C O), 1634, 1521, 1457, 1370, 1244, 1050 cm
-1
; 
1
H NMR (500 MHz, 293K, 
CDCl3) δ 6.27 (dqd, 1H, J = 8.0, 6.5, 1.0 Hz, 4'-H), 6.00 (br d, 1H, J = 9.0 Hz, NH), 5.90 (dd, 
1H, J = 11.5, 8.0 Hz, 3'-H), 5.71 (dd, 1H, J = 11.5, 1.0 Hz, 2'-H), 5.40 (dd, 1H, J = 17.0, 10.5 Hz, 
7-H), 4.91 (dd, 1H, J = 17.0, 1.0 Hz, 7'-H), 4.84 (dd, 1H, J = 10.5, 1.0 Hz, 7'-H), 3.96 (dddd, 1H, 
J = 9.0, 5.5, 2.5, 2.5 Hz), 3.69 (qd, 1H, J = 6.5, 2.5 Hz), 3.54 (dt, 1H, J = 7.0, 2.5 Hz), 2.05 (s, 
3H, 2''-H), 1.99–1.97 (m, 2H), 1.86–1.81 (m, 1H), 1.77–1.72 (m, 1H), 1.40 (d, 3H, J = 6.5 Hz), 
1.35–1.30 (m, 1H), 1.17 (s, 3H), 1.16 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.5 Hz), 0.83 (m, 1H), 
0.77 (dd, 1H, J = 8.5, 4.0 Hz), 0.30 (dd, 1H, J = 5.5, 4.0 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) 
δ 170.6, 165.1, 147.7, 143.8, 122.8, 109.2, 81.5, 76.2, 69.2, 47.4, 36.3, 32.9, 29.4, 22.6, 21.9, 
21.5, 21.1, 20.2, 18.1, 16.0, 15.5; HRMS (EI ) calcd. for C21H33NO4 [M]
+
 363.2410, found 
363.2425. 
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Preparation of 85. A 10-mL, single-necked, round-bottomed flask equipped with a 
Teflon-coated magnetic stir bar and a rubber septum was charged with 84 (23.6 mg, 65.8 mol) 
and THF (1 mL). The mixture was cooled in an ice-water bath and then K2CO3 (22.4 mg, 162 
 57 
mol) was added. After 2 h at 0 °C, saturated aqueous NH4Cl (60 L) was added. The resulting 
mixture was stirred for 5 min, dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. 
The residue was used in the next step without further purification. 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with the crude residue 
(20.9 mg, 64.9 mol), CH2Cl2 (1 mL) and 1,1'-carbonyldiimidazole (26.5 mg, 163 mol). The 
resulting mixture was stirred at 23 °C for 13 h and then morpholine (28.5 L, 327 mol) was 
added. The stirring was continued for 7 h at 23 °C, and the solvent was removed. The reside was 
purified by flash chromatography (10 to 50% EtOAc in hexanes) on silica gel (6 mL) to afford 
85 (26.7 mg, 94%) as a colorless oil. 
Data for 85: Rf = 0.37 (70% EtOAc in hexanes); IR (neat): 3356, 2961, 2927, 2854, 1702 
(C O), 1669 (C O), 1634, 1519, 1457, 1423, 1365, 1316, 1279, 1241, 1117, 1063, 1018 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 6.19–6.13 (m, 2H), 5.92 (dd, 1H, J = 11.5, 8.0 Hz, 3'-H), 
5.71 (dd, 1H, J = 11.5, 1.0 Hz, 2'-H), 5.40 (dd, 1H, J = 17.0, 10.5 Hz, 7-H), 4.91 (dd, 1H, J = 
17.0, 1.5 Hz, 7'-H), 4.84 (dd, 1H, J = 10.5, 1.5 Hz, 7'-H), 3.96 (dq, 1H, J = 9.0, 3.0 Hz), 3.69 (dq, 
1H, J = 6.0, 2.0 Hz), 3.66 (t, 4H, J = 4.5 Hz), 3.54 (dt, 1H, J = 7.0, 2.5 Hz), 3.47 (t, 4H, J = 4.5 
Hz), 1.98–1.97 (m, 2H), 1.86–1.81 (m, 1H), 1.76–1.71 (m, 1H), 1.42 (d, 3H, J = 6.5 Hz), 1.37–
1.30 (m, 1H), 1.17 (s, 3H), 1.16 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.5 Hz), 0.83 (m, 1H), 0.77 
(dd, 1H, J = 9.0, 4.5 Hz), 0.29 (dd, 1H, J = 6.0, 4.5 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 
164.9, 154.9, 147.5, 144.1, 122.3, 108.9, 81.2, 75.9, 70.1, 66.6, 64.6, 47.2, 36.0, 32.7, 29.7, 29.2, 
22.4, 21.7, 20.9, 20.2, 17.9, 15.8, 15.2; MS (ESI+) m/z 435 [M+H]
+
; HRMS (ES ) calcd. for 
C24H38N2O5Na [M Na]
+
 457.2678, found 457.2643. 
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Preparation of 71. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 85 (22 mg, 51 μmol), 86 (17 mg, 86 μmol) and toluene (0.5 mL), followed by 
benzoquinone (1.1 mg, 10 μmol) and 56 (3.4 mg, 5.1 μmol). The resulting mixture was heated to 
70 °C and stirred at the same temperature. After 14 h, the mixture was cooled to 23 °C and 
concentrated in vacuo. The residue was purified by flash chromatography (10 to 80% EtOAc in 
hexanes) on silica gel (5 mL) to afford 71 (7.2 mg, 23%) as a solid, and a mixture of 85 and 86 
(24 mg). 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with the mixture of 85 
and 86 (24 mg) and toluene (0.3 mL), followed by benzoquinone (1.0 mg, 10 μmol) and 56 (3.0 
mg, 4.5 μmol). The resulting mixture was heated to 70 °C. After 22 h at the same temperature, 
the mixture was cooled to 23 °C and concentrated in vacuo. The residue was purified by flash 
chromatography (10 to 80% EtOAc in hexanes) on silica gel (5 mL) to afford 71 (1.8 mg, 7%) as 
a solid. The combined yield of 71 after one cycle is 9.0 mg (30%). 71 was further purified by 
preparative TLC, and afforded as a white solid. 
Data for 71: Rf = 0.14 (70% EtOAc in hexanes); IR (neat): 3345, 2954, 2925, 2867, 1709 
(C O), 1672 (C O), 1635, 1612, 1510, 1457, 1365, 1108, 1003 cm
-1
; 
1
H NMR (600 MHz, 293K, 
C6D6) δ 6.72 (dq, 1H, J = 6.6, 6.6 Hz, 4'-H), 6.06 (d, 1H, J = 9.0 Hz, NH), 5.76 (dd, 1H, J = 11.4, 
7.8 Hz, 3'-H), 5.66 (dd, 1H, J = 15.6, 6.6 Hz, 6-H), 5.53 (d, 1H, J = 15.6 Hz, 7-H), 5.31 (dd, 1H, 
 59 
J = 11.4, 1.2 Hz, 2'-H), 4.46 (dd, 1H, J = 9.0, 6.6 Hz), 4.04–4.01 (m, 1H), 3.29–3.24 (m, 2H), 
3.18 (br s, 6H), 3.15 (s, 3H, 4-OMe), 3.06 (br s, 2H), 2.93 (d, 1H, J = 9.6 Hz, 4-H), 2.74 (d, 1H, 
J = 5.4 Hz, 18-H), 2.07 (d, 1H, J = 5.4 Hz, 18-H), 1.79 (d, 1H, J = 14.4 Hz, 2-H), 1.59–1.54 (m, 
2H), 1.49 (d, 3H, J = 6.6 Hz), 1.47 (s, 3H), 1.42–1.36 (m, 2H), 1.21 (s, 3H), 1.13 (d, 3H, J = 6.6 
Hz), 1.12 (s, 3H), 1.05 (d, 1H, J = 13.8 Hz, 2-H), 0.93–0.88 (m, 1H), 0.91 (d, 3H, J = 7.2 Hz), 
0.70 (dd, 1H, J = 8.4, 4.2 Hz), 0.20 (dd, 1H, J = 4.8, 4.8 Hz); 
13
C NMR (150 MHz, 293K, C6D6) 
δ 164.6, 154.6, 143.0, 142.1, 124.3, 123.1, 81.0, 79.4, 75.8, 73.4, 72.8, 69.9, 60.0, 56.5, 47.1, 
47.0, 43.6, 35.9, 32.9, 31.2, 29.3, 23.8, 22.7, 20.9, 20.7, 20.4, 17.9, 16.5, 15.0; HRMS (ESI ) 
calcd. for C33H52N2O8Na [M Na]
+
 627.3621, found 627.3658. 
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Preparation of 79. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with diethylzinc (2.57 mL, 1.47 mmol) and CH2Cl2 (3.0 mL). The solution was cooled 
in an ice-water bath and diiodomethane (0.170 mL, 2.05 mmol) was added slowly via a syringe. 
The resulting mixture was stirred at 0 °C for 10 min, and a mixed solution of (R,R)-
dioxaborolane 77 (158 mg, 0.585 mmol) and 74 (92.0 mg, 0.294 mmol) in CH2Cl2 (3.0 mL) was 
added via cannula. After the addition, the reaction mixture was warmed to 23 °C and stirred at 
the same temperature for 30 min. Saturated aqueous NH4Cl (3 mL) was added, and the mixtrue 
was extracted with EtOAc (3 × 15 mL). The combined organic layers were washed with brine 
(10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue 
 60 
was purified by flash chromatography (10 to 40% EtOAc in hexanes) on silica gel (8 mL) to 
afford 79 (85.1 mg, 88%, dr = 11:1) as a colorless oil. 
Data for 79: Rf = 0.35 (60% EtOAc in hexanes); IR (neat): 3457, 2975, 2930, 1715 
(C O), 1499, 1391, 1366, 1345, 1237, 1171, 1080, 1058 cm
-1
; 
1
H NMR (500 MHz, 293K, 
CDCl3) δ 4.80 (br d, 1H, J = 9.5 Hz, NH), 3.62 (dq, 1H, J = 6.5, 2.0 Hz), 3.57–3.55 (m, 1H), 
3.49 (dt, 1H, J = 7.0, 2.0 Hz), 3.36 (d, 1H, J =11.0 Hz, 7-H), 3.27 (d, 1H, J = 11.0 Hz, 7-H), 
1.95–1.88 (m, 1H), 1.92 (t, 2H, J = 4.0 Hz), 1.82–1.75 (m, 1H), 1.43 (s, 9H), 1.30–1.24 (m, 1H), 
1.15 (d, 3H, J = 6.5 Hz), 1.14 (s, 3H), 1.02 (d, 3H, J = 7.5 Hz), 0.71–0.66 (m, 1H), 0.56 (dd, 1H, 
J = 9.0, 4.5 Hz), 0.07 (dd, 1H, J = 5.0, 5.0 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 156.0, 81.5, 
79.1, 76.3, 72.3, 48.4, 36.0, 31.9, 29.4, 28.4, 21.9, 17.9, 17.7, 16.5, 15.5, 15.0; MS (EI+) m/z 210 
[M – H2NBoc]
+
;  HRMS (EI ) calcd. for C17H30NO4 [M CH3]
+
 312.2175, found 312.2168. 
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Preparation of 87. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 79 (115 mg, 0.351 mmol) and CH2Cl2 (2.5 mL). The mixture was cooled in an ice-
water bath, and a solution of TFA in CH2Cl2 (1:4 v/v, 2.5 mL) was added slowly via a syringe. 
The reaction was warmed to 23 °C and stirred at the same temperature for 3 h. After 
concentration of the mixture, heptanes (4 mL) was added and removed in vacuo. The residue was 
dissolved in MeCN (4 mL) and used in the next step.  
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Preparation of 89. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 88 (121 mg, 0.528 mmol), MeCN (4 mL) and O-(7-azabenzotriazol-1-yl)-
N,N,N′,N′-tetramethyluronium hexafluorophosphate (201 mg, 0.529 mmol), followed by N, N′-
diisopropylethylamine (0.240 mL, 1.40 mmol). The resulting mixture was added to a stirred 
solution of 87 in MeCN (3 mL) at 23 °C and rinsed with additional MeCN (1 mL). After 10 min 
at 23 °C, saturated aqueous NH4Cl (3 mL) was added, and the mixture was extracted with EtOAc 
(3 × 20 mL). The combined organic layers were washed with brine (10 mL), dried over 
anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by flash 
chromatography (70 to 100% EtOAc in hexanes) on silica gel (15 mL) to afford 89 (115 mg, 
75%) as a white solid. 
Data for 89: Rf = 0.20 (EtOAc); IR (neat): 3585, 3420, 3207, 2921, 1668 (C O), 1519, 
1438, 1378, 1279, 1252, 1111, 1048 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 6.19 (br d, 1H, J 
= 9.5 Hz, NH), 6.17–6.12 (m, 1H, 4'-H), 5.93 (dd, 1H, J = 11.5, 8.0 Hz, 3'-H), 5.71 (dd, 1H, J = 
11.5, 1.5 Hz, 2'-H), 3.97–3.93 (m, 1H), 3.69 (dq, 1H, J = 6.5, 2.5 Hz), 3.66 (t, 4H, J = 4.5 Hz), 
3.52 (ddd, 1H, J = 7.0, 5.0, 3.0 Hz), 3.47 (t, 4H, J = 4.5 Hz), 3.38 (d, 1H, J = 11.0 Hz, 7-H), 3.29 
(d, 1H, J = 11.0 Hz, 7-H), 1.98 (t, 2H, J = 3.5 Hz), 1.85–1.82 (m, 1H), 1.51–1.47 (m, 2H), 1.41 
(d, 3H, J = 6.5 Hz), 1.16 (d, 3H, J = 6.0 Hz), 1.15 (s, 3H), 1.03 (d, 3H, J = 7.5 Hz), 0.73–0.67 
(m, 1H), 0.57 (dd, 1H, J = 8.5, 4.5 Hz), 0.08 (dd, 1H, J = 5.0, 5.0 Hz); 
13
C NMR (75 MHz, 
293K, CDCl3) δ 164.9, 154.9, 144.2, 122.2, 81.6, 75.9, 70.1, 66.6, 47.1, 35.9, 31.9, 29.2, 22.0, 
20.5, 20.2, 17.9, 16.5, 15.5, 15.1; 
13
C NMR (75 MHz, 293K, CDCl3) δ 170.6, 164.3, 143.7, 
 62 
122.8, 81.9, 76.2, 72.7, 69.2, 47.4, 36.2, 32.4, 29.9, 29.7, 22.4, 21.5, 20.2, 18.9, 18.1, 16.9, 16.1; 
HRMS (EI ) calcd. for C23H38N2O6 [M]
+
 438.2730, found 438.2743. 
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Preparation of 90. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 89 (56.1 mg, 0.128 mmol) and CH2Cl2 (3.0 mL). The solution was cooled in an ice-
water bath, and Dess-Martin periodinane (108 mg, 0.255 mmol) were added. The reaction was 
stirred at 0 °C for 5 h, and saturated aqueous NaHCO3 (3 mL) and Na2SO3 (320 mg) were added. 
The stirring was continued for 30 min, and the mixture was extracted with EtOAc (3 × 10 mL). 
The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, 
filtered, and concentrated in vacuo. The crude residue was purified by flash chromatography (30 
to 90% EtOAc in hexanes) on silica gel (6 mL) to afford 90 (32.1 mg, 57%) as a white solid. 
Data for 90: Rf = 0.28 (80% EtOAc in hexanes); IR (neat): 2927, 1697 (C O), 1520, 
1434, 1385, 1278, 1247, 1118, 1073 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 8.67 (s, 1H, 7-
H), 6.16–6.13 (m, 2H), 5.93 (dd, 1H, J = 12.0, 8.0 Hz, 3'-H), 5.71 (dd, 1H, J = 12.0, 1.0 Hz, 2'-
H), 3.97 (dq, 1H, J = 9.0, 2.5 Hz), 3.68 (dq, 1H, J = 6.5, 2.5 Hz), 3.67 (t, 4H, J = 4.5 Hz), 3.52 
(ddd, 1H, J = 8.0, 5.0, 3.0 Hz), 3.47 (t, 4H, J = 4.5 Hz), 1.99–1.98 (m, 2H), 1.85–1.78 (m, 1H), 
1.65–1.59 (m, 1H), 1.54–1.45 (m, 2H), 1.42 (d, 3H, J = 6.5 Hz), 1.37–1.34 (m, 1H), 1.25 (s, 3H), 
1.15 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.5 Hz), 0.73 (dd, 1H, J = 6.5, 5.0 Hz); 
13
C NMR (75 
MHz, 293K, CDCl3) δ 202.5, 165.0, 154.9, 144.2, 122.3, 80.9, 76.0, 70.1, 66.6, 47.0, 35.9, 31.5, 
 63 
29.5, 21.6, 20.2, 19.8, 17.8, 15.1, 11.2; HRMS (ESI ) calcd. for C23H36N2O6Na [M Na]
+
 
459.2471, found 459.2483. 
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Preparation of 91. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with methyltriphenylphosphonium bromide (0.11 g, 0.31 mmol) and THF (2.5 mL). The 
mixture was cooled in an ice-water bath and a solution of KO
t
Bu in THF (0.25 mL, 1 M, 0.25 
mmol) was added. The resulting mixture was stirred at 0 °C for 20 min, and aldehyde 90 (27 mg, 
61 mol) in THF (1 mL) was added via cannula and rinsed with additional THF (1 mL). After 10 
min at 0 °C, H2O (4 mL) was added. After removal of THF, the mixture was extracted with 
EtOAc (3 × 15 mL). The combined organic layers were washed with brine (5 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The crude residue was purified by flash 
chromatography (20 to 50% EtOAc in hexanes) on silica gel (5 mL) to afford 91 (23.0 mg, 85%) 
as a colorless oil. 
Data for 91: Rf = 0.37 (70% EtOAc in hexanes); IR (neat): 3358, 2925, 2855, 1702 
(C O), 1669 (C O), 1634, 1516, 1457, 1426, 1367, 1302, 1277, 1241, 1220, 1119, 1074, 1022 
cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 6.19–6.13 (m, 2H), 5.93 (dd, 1H, J = 11.5, 7.5 Hz, 3'-
H), 5.71 (dd, 1H, J = 11.5, 1.0 Hz, 2'-H), 5.41 (dd, 1H, J = 17.0, 10.5 Hz, 7-H), 4.93 (dd, 1H, J = 
17.0, 1.0 Hz, 7'-H), 4.85 (dd, 1H, J = 10.5, 1.0 Hz, 7'-H), 3.96 (dq, 1H, J = 9.0, 3.0 Hz), 3.69 (dq, 
1H, J = 6.5, 2.0 Hz), 3.66 (t, 4H, J = 4.5 Hz), 3.52 (dt, 1H, J = 7.0, 2.5 Hz), 3.47 (t, 4H, J = 4.5 
 64 
Hz), 1.98–1.97 (m, 2H), 1.87–1.81 (m, 1H), 1.67–1.61 (m, 1H), 1.51–1.45 (m, 1H), 1.42 (d, 3H, 
J = 6.5 Hz), 1.17 (s, 3H), 1.16 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.0 Hz), 0.83 (m, 1H), 0.77 
(dd, 1H, J = 8.5, 4.0 Hz), 0.34 (dd, 1H, J = 6.0, 4.5 Hz); 
13
C NMR (75 MHz, 293K, CDCl3) δ 
165.1, 155.2, 147.8, 144.4, 122.5, 109.2, 81.8, 76.1, 70.4, 66.9, 47.4, 36.2, 32.3, 29.9, 29.3, 22.4, 
21.8, 20.9, 20.4, 18.1, 15.9, 15.2; HRMS (ESI ) calcd. for C24H38N2O5Na [M Na]
+
 457.2678, 
found 457.2694. 
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Preparation of 72. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 91 (30 mg, 68 μmol), 86 (18 mg, 95 μmol) and toluene (0.8 mL), followed by 
benzoquinone (1.5 mg, 14 μmol), and 56 (4.5 mg, 6.8 μmol). The resulting mixture was heated to 
70 °C and stirred at the same temperature. After 27 h, the mixture was cooled to 23 °C and 
concentrated in vacuo. The residue was purified by flash chromatography (10 to 80% EtOAc in 
hexanes) on silica gel (15 mL) to afford 72 (6.6 mg, 16%) as a solid, and a mixture of 91 and 86 
(27 mg). 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with the mixture of 91 
and 86 (27mg) and toluene (0.6 mL), followed by benzoquinone (1.0 mg, 10 μmol) and 56 (3.5 
mg, 5.2 μmol). The resulting mixture was heated to 70 °C. After 22 h at the same temperature, 
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the mixture was cooled to 23 °C and concentrated in vacuo. The residue was purified by flash 
chromatography (10 to 80% EtOAc in hexanes) on silica gel (10 mL) to afford 72 (2.5 mg, 6%) 
as a solid. The combined yield of 72 after one cycle is 9.1 mg (22%). 72 was further purified by 
preparative TLC, and afforded as a white solid. 
Data for 72: Rf = 0.14 (70% EtOAc in hexanes); IR (neat): 3359, 2972, 2927, 2855, 1701 
(C O), 1669 (C O), 1638, 1518, 1457, 1425, 1369, 1303, 1276, 1241, 1194, 1120, 1072, 1023, 
1002 cm
-1
; 
1
H NMR (600 MHz, 293K, C6D6) δ 6.69 (dq, 1H, J = 6.6, 6.6 Hz, 4'-H), 6.09 (d, 1H, 
J = 9.0 Hz, NH), 5.74 (dd, 1H, J = 11.4, 7.8 Hz, 3'-H), 5.65 (dd, 1H, J = 15.6, 6.6 Hz, 6-H), 5.50 
(d, 1H, J = 15.6 Hz, 7-H), 5.32 (dd, 1H, J = 11.4, 1.2 Hz, 2'-H), 4.44 (dd, 1H, J = 9.6, 6.6 Hz), 
4.04–4.02 (m, 1H), 3.30–3.27 (m, 1H), 3.26–3.23 (m, 1H), 3.18 (br s, 6H), 3.15 (s, 3H, Me), 3.05 
(br s, 2H), 2.92 (d, 1H, J = 9.6 Hz, 4-H), 2.72 (d, 1H, J = 5.4 Hz, 18-H), 2.06 (d, 1H, J = 5.4 Hz, 
18-H), 1.77 (d, 1H, J = 13.8 Hz, 2-H), 1.73–1.69 (m, 1H), 1.58–1.52 (m, 2H), 1.41–1.38 (m, 
2H), 1.48 (d, 3H, J = 6.6 Hz), 1.46 (s, 3H), 1.19 (s, 3H), 1.17 (s, 3H), 1.14 (d, 3H, J = 6.6 Hz), 
1.04 (d, 1H, J = 13.8 Hz, 2-H), 0.92 (d, 3H, J = 7.8 Hz), 0.86–0.81 (m, 1H), 0.72 (dd, 1H, J = 
9.0, 4.2 Hz), 0.13 (dd, 1H, J = 4.2, 4.2 Hz). 
13
C NMR (150 MHz, 293K, C6D6) δ 165.1, 155.1, 
143.8, 142.5, 124.8, 123.6, 82.0, 80.0, 76.4, 73.9, 73.4, 70.5, 60.6, 57.1, 47.7, 47.6, 44.2, 36.4, 
32.9, 31.8, 29.9, 24.4, 22.7, 21.3, 21.2, 20.9, 18.4, 16.8, 15.4; HRMS (ESI ) calcd. for 
C33H52N2O8Na [M Na]
+
 627.3621, found 627.3627. 
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Preparation of 97. An oven-dried, 1000-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
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charged with 96 (33.8 g, 0.286 mol), CH2Cl2 (300 mL) and CDI (48.7 g, 0.300 mol). The 
resulting mixture was stirred at 23 °C for 20 h and then cooled to 0 °C. Morpholine (37.4 g, 
0.429 mol) was added dropwise. After the addition, the mixture was warmed to 23 °C, stirred for 
an additional 2 h, and concentrated in vacuo. The residue was purified by dry column vacuum 
chromatography (10 to 70% EtOAc in hexanes) on silica gel (1000 mL) to afford 97 (58.1 mg, 
88%) as colorless liquid.  
Data for 97: Rf = 0.33 (40% EtOAc in hexanes); [α]D
22
 +18.3 (c 1.00, CHCl3); IR (neat): 
3494, 2984, 2859, 1753 (C O), 1710 (C O), 1430, 1371, 1302, 1277, 1245, 1203, 1113, 1048, 
1021 cm
-1
; 
1
H NMR (300 MHz, 293K, CDCl3) δ 5.01 (q, 1H, J = 7.2 Hz, 4'-H), 4.17 (q, 2H, J = 
7.2 Hz, 1''-H), 3.65 (t, 4H, J = 4.8 Hz, mor-CH2O), 3.48 (br s, 4H, mor-CH2N), 1.45 (d, 3H, J = 
6.9 Hz, 5'-H), 1.25 (t, 3H, J = 7.2 Hz, 2''-H); 
13
C NMR (75 MHz, 293K, CDCl3) δ 171.4, 154.5, 
69.5, 66.5, 61.2, 44.3, 17.1, 14.1; HRMS (EI ) calcd. for C10H17NO5 [M]
+
 231.1107, found 
231.1098. 
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Preparation of 100. An oven-dried, 1000-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 98 (128 g, 0.296 mol) and THF (300 mL). The solution was cooled in an ice-water 
bath, and NaH (11.4 g, 60%, 0.285 mol) was added in portions. The resulting mixture was stirred 
at 0 °C over 0.5 h before use. 
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An oven-dried, 2000-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with 97 
(45.6 g, 0.197 mol), and CH2Cl2 (450 mL). The solution was cooled in a dry ice-acetone bath, 
and DIBALH (207 mL, CH2Cl2, 0.207 mol) was added dropwise via a syringe over 50 min. After 
the addition, the ylide solution was added slowly via cannula over 20 min. The mixture was 
warmed to 23 °C slowly and stirred at the same temperature for 4.5 h. Then reaction was cooled 
to 0 °C, and EtOAc (500 mL) and HCl (1 M, 500 mL) were added. The mixture was separated, 
and the aqueous layer was extracted by EtOAc (3 × 250 mL). The combined organic layers were 
washed with brine (2 × 100 mL), dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo. The crude residue was purified by dry column vacuum chromatography (10 to 50% 
EtOAc in hexanes) on silica gel (1000 mL) to afford 100 (45.1 g, 89%) as a colorless oil. 
Data for 100: Rf = 0.34 (40% EtOAc in hexanes); [α]D
22
 +45.0 (c 1.12, CHCl3); IR (neat): 
2966, 2862, 1708 (C O), 1487, 1426, 1367, 1300, 1278, 1242, 1195, 1118, 1088, 1053, 1025 
cm
-1
; 
1
H NMR (300 MHz, 293K, CDCl3) δ 6.20 (dq, 1H, J = 8.1, 6.3 Hz), 6.16 (dd, 1H, J = 10.5, 
8.1 Hz), 5.77 (d, 1H, J = 10.5 Hz, 4'-H), 4.18 (q, 2H, J = 7.2 Hz, 1''-H), 3.65 (t, 4H, J = 4.5 Hz, 
mor-CH2O), 3.45 (t, 4H, J = 4.5 Hz, mor-CH2N), 1.38 (d, 3H, J = 6.3 Hz, 5'-H), 1.29 (t, 3H, J = 
6.9 Hz, 2''-H); 
13
C NMR (75 MHz, 293K, CDCl3) δ 165.6, 155.0, 149.3, 119.6, 70.0, 66.8, 60.6, 
20.0, 14.4, 14.3; HRMS (EI ) calcd. for C12H19NO5 [M]
+
 257.1263, found 257.1257. 
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Preparation of 106. An oven-dried, 25-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 3-butenal diethyl acetal (0.33 g, 2.3 mmol), methacrolein (2.90 mL, 34.6 mmol) 
and 56 (15 mg, 23 μmol). The resulting of mixture was stirred at 23 °C for 8 h and concentrated 
in vacuo. The residue was purified by flash chromatography (5 to 30% Et2O in hexanes) on silica 
gel (25 mL) to afford 106 (0.22 mg, 52%) as colorless liquid. 
Data for 106: Rf = 0.25 (10% EtOAc in hexanes); IR (neat): 2976, 2881, 2711, 1689 
(C O), 1647, 1444, 1374, 1344, 1201, 1124, 1062 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 
9.44 (s, 1H, 7-H), 6.56 (td, 1H, J = 7.0, 1.5 Hz, 9-H), 4.66 (t, 1H, J = 5.5 Hz, 11-H), 3.69 (dq, 
2H, J = 9.5, 7.0 Hz, 1'-H), 3.55 ( dq, 2H, J = 9.5, 7.0 Hz, 7'-H), 2.70 (td, 2H, J = 7.0, 1.0 Hz, 10-
H), 1.77 (d, 3H, J = 1.0 Hz, 19-H), 1.23 (t, 6H, J = 7.0 Hz, 2'-H); 
13
C NMR (75 MHz, 293K, 
CDCl3) δ 195.1, 148.5, 140.9, 101.2, 61.8, 34.0, 15.3, 9.4;  
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Preparation of 94. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with methyltriphenylphosphonium bromide (0.719 g, 2.14 mmol) and THF (6 mL). The 
solution was cooled in an ice-water bath, and a solution of KO
t
Bu (1M, 1.90 mL, 1.90 mmol) in 
THF was added via a syringe. The mixture was stirred for 10 min at 0 °C, and a solution of 106 
(201 mg, 1.07 mmol) in THF (5 mL) was added via cannula. After 10 min, H2O (5 mL) was 
added. After removal of THF, the mixture was extracted with Et2O (3 × 20 mL). The combined 
organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered and 
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concentrated in vacuo. The crude residue was purified by flash chromatography (hexanes) on 
silica gel (20 mL) to afford 94 (137 mg, 63%) as a colorless oil. 
Data for 94: Rf = 0.25 (2% EtOAc in hexanes); IR (neat): 3433, 3090, 2976, 2880, 1644, 
1608, 1443, 1373, 1343, 1205, 1128, 1063, 1015 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 6.40 
(dd, 1H, J = 17.5, 10.5 Hz, 7-H), 5.51 (t, 1H, J = 7.0 Hz, 9-H), 5.12 (d, 1H, J = 17.5 Hz, 7'-H), 
4.96 (d, 1H, J = 10.5 Hz, 7'-H), 4.53 (t, 1H, J = 6.0 Hz, 11-H), 3.66 ( dq, 2H, J = 9.5, 7.0 Hz, 1'-
H), 3.52 ( dq, 2H, J = 9.5. 7.0 Hz, 1'-H), 2.50 (t, 2H, J = 6.5 Hz, 10-H), 1.76 (d, 3H, J = 1.0 Hz, 
19-H), 1.22 (t, 6H, J = 7.0 Hz, 2'-H); 
13
C NMR (75 MHz, 293K, CDCl3) δ 141.7, 136.3, 127.3, 
111.4, 102.7, 61.6, 33.5, 15.7, 12.3;  
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Preparation of 93. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 88 (0.535 mg, 2.33 mmol), 95 (0.270 mg, 2.59 mmol), MeCN (15 mL), and O-(7-
azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (0.629 mg, 2.33 
mmol). And N, N′-diisopropylethylamine (0.810 mL, 4.66 mmol) was added to the mixture 
slowly via a syringe. The resulting mixture was stirred at 23 °C for 20 min and saturated aqueous 
NH4Cl (0.5 mL) was added. The mixture was dried over anhydrous Na2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by flash chromatography (2 to 10 % 
MeOH in EtOAc) on silica gel (25 mL) to afford 93 (0.717 g, 97%) as a white solid. 
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Data for 93: Rf = 0.32 (10% MeOH in CH2Cl2); [α]D
22
 +22.4 (c 1.00, CHCl3); IR (neat): 
3405, 2972, 2930, 2863, 1671 (C O), 1538, 1432, 1372, 1301, 1278, 1246, 1116, 1050, 1022 
cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 7.39 (br d, 1H, J = 9.0 Hz, NH), 6.00 (d, 1H, J = 11.0 
Hz, 2'-H), 5.76 ( dq, 1H, J = 10.0, 6.5 Hz, 4'-H), 5.72 (dd, 1H, J = 11.0, 10.0 Hz, 3'-H), 4.21 (qd, 
1H, J = 6.5, 2.5 Hz), 4.03 (dd, 1H, J = 11.5, 2.5 Hz), 3.84–3.79 (m, 2H, mor-CH2O), 3.66 (s, 4H, 
mor-CH2N), 3.45 (d, 4H, J = 16.5 Hz), 1.39 (d, 3H, J = 6.0 Hz), 1.22 (d, 3H, J = 6.5 Hz); 
13
C 
NMR (75 MHz, 293K, CDCl3) δ 167.2, 155.7, 137.5, 126.8, 70.2, 70.1, 66.7, 65.8, 55.7, 20.8, 
20.6; HRMS (ESI ) calcd. for C14H24N2O6Na [M+Na]
+
 339.1532, found 339.1517. 
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Preparation of 107. An oven-dried, 50-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 93 (0.250 mg, 0.790 mmol), 94 (0.146 mg, 0.790 mmol) and CH2Cl2 (6 mL), 
followed by CSA (36.7 mg, 0.158 mmol). Et3N (50 μL) was added, and the solution was 
removed in vacuo. The crude residue was purified by flash chromatography (50 to 90% EtOAc 
in hexanes) on silica gel (30 mL) to afford 107 (121 mg, 38%) as a white solid. 
Data for 107: Rf = 0.20 (60% EtOAc in hexanes); [α]D
22
 +4.5 (c 1.00, CHCl3); IR (neat): 
3322, 2978, 2930, 2860, 1695 (C O), 1671 (C O), 1525, 1428, 1365, 1278, 1243, 1120, 1052, 
1022 cm
-1
; 
1
H NMR (500 MHz, 293K, CDCl3) δ 7.36 (br d, 1H, J = 9.0 Hz, NH), 6.38 (dd, 1H, J 
= 17.0, 11.0 Hz, 7-H), 5.99 (dq, 1H, J = 6.5, 6.5 Hz, 4'-H), 5.89–5.83 (m, 2H), 5.52 (t, 1H, J = 
6.5 Hz, 9-H), 5.13 (d, 1H, J = 17.0 Hz, 7'-H), 4.97 (d, 1H, J = 11.0 Hz, 7'-H), 4.65 (t, 1H, J = 5.0 
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Hz, 11-H), 4.03 (dd, 1H, J = 12.0, 1.5 Hz), 3.97–3.93 (m, 2H), 3.89 (dd, 1H, J = 12.0, 1.5 Hz), 
3.65 (t, 4H, J = 4.5 Hz, mor-CH2O), 3.47 (s, 4H, mor-CH2N), 2.51 (t, 2H, J = 6.0 Hz, 10-H), 
1.75 (d, 3H, J = 0.5 Hz, 19-H), 1.39 (d, 3H, J = 6.5 Hz), 1.18 (d, 3H, J = 6.5 Hz); 
13
C NMR (75 
MHz, 293K, CDCl3) δ 165.8, 155.3, 142.2, 141.2, 136.7, 126.1, 123.7, 111.7, 102.2, 74.9, 71.4, 
70.1, 66.9, 47.1, 44.4, 34.5, 20.7, 17.9, 12.3; HRMS (ESI ) calcd. for C21H32N2O6Na [M+Na]
+
 
431.2158, found 431.2142. 
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Preparation of 92. An oven-dried, 10-mL, single-necked, round-bottomed flask 
equipped with a Teflon-coated magnetic stir bar, a rubber septum and a nitrogen inlet was 
charged with 107 (57 mg, 0.14 mmol), 59 (35 mg, 0.19 mol) and DCE (2 mL), followed by 
benzoquinone (3.0 mg, 28 μmol), and 56 (9.3 mg, 14 μmol). The resulting mixture was heated to 
43 °C, and stirred at the same temperature. After 27 h, the reaction mixture was concentrated in 
vacuo. The residue was purified by flash chromatography (20 to 90% EtOAc in hexanes) on 
silica gel (10 mL) to afford 92 (12 mg, 15%) as a solid, and a mixture of 107 and 59 (37 mg). 
An oven-dried, 10-mL, single-necked, round-bottomed flask equipped with a Teflon-
coated magnetic stir bar, a rubber septum and a nitrogen inlet was charged with the mixture of 
107 and 59 (37 mg) and DCE (1 mL), followed by benzoquinone (1.1 mg, 11 μmol) and 56 (3.5 
mg, 5.2 μmol). The resulting mixture was heated to 45 °C, and stirred at the same temperature. 
After 20 h, the reaction mixture was concentrated in vacuo. The residue was purified by flash 
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chromatography (20 to 90% EtOAc in hexanes) on silica gel (8 mL) to afford 92 (3.1 mg, 6%) as 
a solid. The combined yield of 92 after one cycle is 14.8 mg (19%). 92 was further purified by 
preparative TLC, and afforded as a white solid. 
Data for 92: Rf = 0.11 (80% EtOAc in hexanes); [α]D
22
 +13.8 (c 0.40, CHCl3); IR (neat): 
3427, 2925, 1670 (C O), 1530, 1429, 1366, 1277, 1244, 1122, 1051 cm
-1
; 
1
H NMR (600 MHz, 
293K, CD2Cl2) δ 7.11 (br d, 1H, J = 9.6 Hz, NH), 6.34 (d, 1H, J = 15.6 Hz, 7-H), 6.01 (dq, 1H, J 
= 6.6, 6.6 Hz, 4'-H), 5.88 (dd, 1H, J = 12.0, 8.4 Hz, 3'-H), 5.81 (dd, 1H, J = 12.0, 0.6 Hz, 2'-H), 
5.65 (dd, 1H, J = 15.6, 6.6 Hz, 6-H), 5.52 (t, 1H, J = 7.2 Hz, 9-H), 4.63 (t, 1H, J = 5.4 Hz, 11-H), 
3.98–3.92 (m, 3H), 3.90–3.87 (m, 2H), 3.61 (s, 4H, mor-CH2O), 3.48 (t, 1H, J = 10.2 Hz, 4-H), 
3.43 (s, 4H, mor-CH2N), 2.96 (d, 1H, J = 4.8 Hz, 18-H), 2.52–2.43 (m, 2H), 2.46 (d, 1H, J = 4.8 
Hz, 18-H), 2.16 (d, 1H, J = 14.4 Hz, 2-H), 1.76 (s, 3H), 1.62 (d, 1H, J = 10.8 Hz, 4-OH), 1.39 (d, 
1H, J = 14.4 Hz, 2-H), 1.35 (s, 3H), 1.34 (d, 3H, J = 6.6 Hz), 1.23 (s, 3H), 1.12 (d, 3H, J = 6.6 
Hz); HRMS (EI ) calcd. for C29H44N2O9 [M]
+
 564.3047, found 564.3058. 
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1.3 1H AND 13C SPECTRA 
1
H NMR of 47: CDCl3, 293 K, 600 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
1H  @ 600 MHz yaw1125
 
13
C NMR of 47: CDCl3, 293 K, 125 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1125 13C NMR, rt, CDCl3 500 MHz  Nov 10, 2008
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1
H NMR of 49: CDCl3, 293 K, 500 MHz 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1100, 1H NMR, rt, CDCl3 500 MHz  Nov 10, 2008
 
 
 
13
C NMR of 49: CDCl3, 293 K, 125 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1100, 13C NMR, rt, CDCl3 500 MHz  Nov 10, 2008
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1
H NMR of 50: CDCl3, 293 K, 500 MHz 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0 ppm
yaw1246, 1H NMR, rt, CDCl3 CD3OD 500 MHz  Jan 2, 2009
 
13
C NMR of 50: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1246 1H NMR, rt, 300MHz CDCl3, Jan 3,  2009
HN
HO
OO
(dr = 6:1)
HN
HO
OO
(dr = 6:1)
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1
H NMR of 52: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1131, 1H NMR, rt, CDCl3 (1% CD3OD), August 15, 2008
 
13
C NMR of 52: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1131, r.t., CDCl3, 300MHz, 13C NMR, 301 a,  July 23, 2009
OH OH
NHBoc
(dr = 6:1)
OH OH
NHBoc
(dr = 6:1)
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1
H NMR of 53: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1131, r.t., CDCl3, 300MHz, 1H NMR, 301 a,  July 21, 2009
 
 
13
C NMR of 53: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1130, r.t., CDCl3, 300MHz, 1H NMR, 301 a,  July 22, 2009
51
O
O
BocHN
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O
BocHN
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1
H NMR of 55: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1194, 1H NMR, rt, CDCl3 (1% CD3OD), September 25, 2008
 
13
C NMR of 55: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1194, 13C NMR, rt, CDCl3 , September 25, 2008
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1
H NMR of 57: CDCl3, 293 K, 300 MHz 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw1197, 1H NMR, rt, CDCl3, September 27, 2008
 
13
C NMR of 57: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1195, 13C NMR CDCl3, r.t., September 26, 2008
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1
H NMR of 58: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
1H NMR, YAW1198
 
13
C NMR of 58: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1212 13H 600MHz 10/14/08
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1
H NMR of 41: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1206, 1H NMR, rt, CD3Cl 500 MHz  Oct 27 2008
 
13
C NMR of 41: CDCl3, 293 K, 300 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
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1
H NMR of 64: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2098, 1H NMR , CDCl3,  RT 300MHz, 300, June 30, 2009
 
13
C NMR of 64: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2098, 13C NMR , CDCl3,  RT 300MHz, 300, June 30, 2009
O
O
N
H
O
AcO
65
O
O
N
H
O
AcO
65
 83 
1
H NMR of 65: CDCl3, 293 K, 300 MHz 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw2102, 1H NMR , CDCl3,  RT 300MHz, 300, July 1, 2009
 
13
C NMR of 65: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw2102, 13C NMR , CDCl3,  RT 300MHz, 300, July 1, 2009
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1
H NMR of 66: CDCl3, 293 K, 300 MHz  
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2103, 1H NMR , CDCl3,  RT 300MHz, 300, July 2, 2009
 
13
C NMR of 66: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2103, 13C NMR , CDCl3,  RT 300MHz, 300, July 2, 2009
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1
H NMR of 42: CDCl3, 293 K, 600 MHz 
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2104 r.t., 1H NMR, CD2Cl2, 600MHz,  July 15, 2009
 
13
C NMR of 42: CDCl3, 293 K, 150 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2104 r.t., 13C NMR, CD2Cl2, 600MHz,  July 15, 2009
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1
H NMR of 75: CDCl3, 293 K, 300 MHz 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw1233, r.t., CDCl3, 300MHz, 1H-NMR, 10/27/2008
 
13
C NMR of 75: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1233 13C NMR , CDCl3  RT 75MHz   Oct 27,2008
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1
H NMR of 74: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1234 1H NMR, rt, 300MHz CDCl3, Oct. 28 2008
 
13
C NMR of 74: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1234 13C NMR , CDCl3  RT 75MHz   Oct 28,2008
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1
H NMR of 78: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
yaw1245 1H NMR , CDCl3  RT 300MHz   NOv 11,2008
 
13
C NMR of 78: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1245 13C NMR , CDCl3  RT 300MHz   NOv 11,2008
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 89 
1
H NMR of 81: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
1H NMR YAW1264
 
13
C NMR of 81: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
1H NMR YAW1264
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1
H NMR of 83: CDCl3, 293 K, 500 MHz 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw1267, 13C NMR, rt, CDCl3 500 MHz  Nov 22, 2008
 
13
C NMR of 83: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1267 13C NMR , CDCl3  RT 300MHz   NOv 23,2008
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1
H NMR of 84: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1271, 1H NMR, rt, CDCl3 500 MHz  Nov 24, 2008
 
13
C NMR of 84: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1271 13C NMR , CDCl3  RT 300MHz   Nov 24,2008
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 92 
1
H NMR of 85: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2019, 1H NMR, rt, CDCl3 500 MHz  Mar 12, 2009
 
13
C NMR of 85: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2019 13c NMR , CDCl3  RT 300MHz   Mar 14,2009
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 93 
1
H NMR of 71: CDCl3, 293 K, 600 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2090 r.t., 1H NMR, C6D6, 600MHz,  June 27, 2009
 
 
13
C NMR of 71: CDCl3, 293 K, 150 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2090 r.t., 13C NMR, C6D6, 600MHz,  June 27, 2009
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1
H NMR of 79: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
yaw1282, 1H NMR, rt, CDCl3 500 MHz  Sep 09, 2009
 
13
C NMR of 79: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1282, 301B, CDCl3, rt, Sep 09, 09
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1
H NMR of 89: CDCl3, 293 K, 500 MHz  
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
yaw2165, 1H NMR, rt, CDCl3 500 MHz  Oct 2, 2009
 
13
C NMR of 89: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2165 13C NMR , CDCl3  RT 300MHz Oct 03, 2009
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1
H NMR of 90: CDCl3, 293 K, 500 MHz 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw1302, 1H NMR, rt, CDCl3 500 MHz  Feb 3, 2009
 
13
C NMR of 90: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw1300 13C NMR , CDCl3  RT 300MHz   Feb 2,2009
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1
H NMR of 91: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1304 1H NMR , CDCl3  RT 300MHz   Mar 13,2009
 
13
C NMR of 91: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw1304 13c NMR , CDCl3  RT 300MHz   Mar 13,2009
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 98 
1
H NMR of 72: CDCl3, 293 K, 600 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw1304 1H NMR , CDCl3  RT 300MHz   Mar 13,2009
 
13
C NMR of 72: CDCl3, 293 K, 150 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2087 r.t., 13C NMR, CD3OD, 600MHz,  June 12, 2009
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 99 
1
H NMR of 97: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2158, 1H, CDCl3,  RT, 300, Oct 21, 2009
 
13
C NMR of 97: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2158, 13C, CDCl3,  RT, 300, Oct 20, 2009
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1
H NMR of 100: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2157, 1H, CDCl3,  RT, 300, Nov 14, 2009
 
13
C NMR of 100: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2157, 13 C, CDCl3,  RT, 300, Nov 14, 2009
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 101 
1
H NMR of 106: CDCl3, 293 K, 500 MHz 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 ppm
yaw2173, 1H NMR, rt, CDCl3 500 MHz  Oct 2, 2009
 
13
C NMR of 106: CDCl3, 293 K, 75 MHz 
200 180 160 140 120 100 80 60 40 20 0 ppm
yaw2173 13C NMR , CDCl3  RT 300MHz Oct 08, 2009
108
OEt
EtO O
108
OEt
EtO O
 102 
1
H NMR of 94: CDCl3, 293 K, 300 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2176, 1H NMR, rt, CDCl3 500 MHz  Oct 16, 2009
 
13
C NMR of 94: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2176 13C NMR , CDCl3  RT 300MHz Oct 13, 2009
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 103 
1
H NMR of 93: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2181 1H NMR , CDCl3  RT 300MHz Oct 19, 2009
 
 
13
C NMR of 93: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2181, 13C, CDCl3,  RT, 300, Oct 19, 2009
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1
H NMR of 107: CDCl3, 293 K, 500 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2186, 1H NMR, rt, CDCl3 500 MHz  Oct 27, 2009
 
13
C NMR of 107: CDCl3, 293 K, 75 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2186, 13C, CDCl3,  RT, 300, Oct 27, 2009
O
O
N
H
O
ON
O
O
109
O
O
N
H
O
ON
O
O
109
 105 
 
1
H NMR of 92: CDCl3, 293 K, 600 MHz 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
yaw2171 r.t., 1H NMR, CD2Cl2, 600MHz,  Oct 23, 2009
 
 
13
C NMR of 92: CDCl3, 293 K, 150 MHz 
190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
yaw2171 r.t., 13C, CD2Cl2, 600MHz,  Oct 23, 2009
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